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Abstract
Outcomes in multiple myeloma (MM) have improved
dramatically in the last two decades with the advent of
novel therapies including immunomodulatory agents
(IMiDs), proteasome inhibitors and monoclonal antibodies.
In recent years, immunotherapy for the treatment of MM
has advanced rapidly, with the approval of new targeted
agents and monoclonal antibodies directed against
myeloma cell-surface antigens, as well as maturing data
from late stage trials of chimeric antigen receptor (CAR) T
cells. Therapies that engage the immune system to treat
myeloma offer significant clinical benefits with durable
responses and manageable toxicity profiles, however,
the appropriate use of these immunotherapy agents can
present unique challenges for practicing physicians.
Therefore, the Society for Immunotherapy of Cancer
convened an expert panel, which met to consider the
current role of approved and emerging immunotherapy
agents in MM and provide guidance to the oncology
community by developing consensus recommendations.
As immunotherapy evolves as a therapeutic option for the
treatment of MM, these guidelines will be updated.

Introduction
Multiple myeloma (MM) is the second most
commonly diagnosed hematological malignancy, with nearly 160 000 new cases worldwide in 2018.1 Before the 21st century, most
patients with MM died within a few years
after diagnosis, yet outcomes have improved
dramatically during the past two decades.
Novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors
(PIs) and monoclonal antibodies (mAbs)
have been incorporated into standard treatment approaches, which had previously been
limited to stem cell transplants, alkylating
agents and steroids.2–6 Additionally, advances
in risk stratification based on cytogenetics7 8 as
well as the ability to detect minimal residual

disease (MRD) with a high degree of sensitivity using multicolor flow cytometry (MFC)
or next-generation sequencing (NGS) technologies9 may further enhance the selection
of treatment strategies both at initial diagnosis
and relapse. Despite these breakthroughs,
however, MM remains largely incurable, with
the vast majority of patients experiencing
relapse at some point.
Advances in understanding of the basic
mechanisms of immune evasion and suppression in MM has led to new therapies with
demonstrated benefits for patients. In
2015, the US Food and Drug Administration (FDA) approved two mAbs for the
treatment of MM, daratumumab (dara)
and elotuzumab,10 11 blazing a trail for the
development of numerous other immunotherapies in this disease setting, including
chimeric antigen receptor (CAR) T cells,12–15
antibody-drug conjugates (ADCs),16–18 bispecific T-cell engagers (BiTEs)19–21 and cancer
vaccines.22 23 As the world’s leading non-
profit member-driven organization dedicated
to advancing cancer immunotherapy, the
Society for Immunotherapy of Cancer (SITC)
develops Cancer Immunotherapy Guidelines
for a variety of disease states. Previously, SITC
published the first-ever consensus statement
for the use of immunotherapy to treat hematological malignancies in 2016.24
Immunotherapy is currently playing
a pivotal role in MM treatment, necessitating clinical practice guidelines with
detailed recommendations specific to these
important, practice-
changing modalities.
Recognizing the rapid pace of advancement of the field, and a need to update the
previously published consensus statement
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with practical guidance on how to incorporate the ever-
growing number of immunotherapeutic agents that
have been approved or are in the final stages of clinical
development into the treatment of MM, SITC convened
an expert panel encompassing perspectives from hematology, medical oncology, hematopathology, nursing and
patient advocacy to provide evidence-based recommendations for the oncology community. This panel met to
consider issues related to patient selection, dosing and
monitoring, toxicity management and quality of life
(QoL), with the goal of preparing a consensus statement
on clinical use of immunotherapy for patients with MM.
In recognition of the rapid pace of advancement of
the immunotherapy field, this consensus statement
will discuss emerging therapies that have not yet, at the
time of publication, received United States Food and
Drug Administration approval. As such, the manuscript
is divided into two sections, based on FDA approval
status at time of publication. Because recommendations
concerning the use of IMiDs were published in the 2016
consensus statement on hematological malignancies,24
those agents are not extensively discussed in these guidelines, except as components of combination regimens
with antibody therapies. Additionally, although allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is an important therapeutic option in the management of
MM, other groups have published consensus recommendations regarding its use25 and therefore a discussion of
the approach was beyond the scope of these guidelines.
As with any consensus statement, the recommendations
contained within this paper are intended to provide guidance and are not a substitute for the professional judgment of individual physicians treating individual patients.

Materials and methods
SITC Multiple Myeloma Immunotherapy Guideline Expert Panel
The SITC Multiple Myeloma Immunotherapy Guideline
Expert Panel consisted of 19 participants, including 17
medical oncologists, 1 nurse practitioner and 1 patient
advocate. One hundred percent of clinical expert panel
members reported previous experience/knowledge
regarding the use of immuno-oncology therapy for the
treatment of patients with MM. The panel communicated regularly via email and teleconference in addition
to completing online surveys (see online supplementary
file 1), addressing clinical topics concerning the use of
cancer immunotherapy for the treatment of patients
with MM, which helped form the basis for consensus
recommendations.
Consensus statement policy
The Institute of Medicine’s (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines were used
as a model to develop the consensus recommendations
in this manuscript. IOM standards dictate that guideline
development is led by a multidisciplinary team using a
transparent process where both funding sources and
2

conflicts of interest are readily reported. Recommendations are based on literature evidence, where possible,
and clinical experience, where appropriate.26 For transparency, a draft of this consensus statement was made
publicly available for comment after journal submission.
All comments were considered for inclusion into the
final manuscript. This consensus statement is intended to
provide guidance and is not a substitute for the professional judgment of individual treating physicians.
Evidence and consensus ratings
Consensus recommendations were derived from evidence
within the published literature along with responses to a
clinical questionnaire that addressed current practices in
the use or recommendation for use of immunotherapy
agents (online supplementary file 1). SITC Cancer
Immunotherapy Guidelines provide recommendations
based on peer-reviewed literature and consensus within
the expert panel. Consensus was defined as ≥75% agreement among expert panel members.
Conflicts of interest policy
As per SITC policy, expert panel members managed
potential competing interests through disclosure of all
financial relationships that might result in actual, potential or perceived conflicts of interest. No commercial
funding was provided to support the expert panel, literature review, or the preparation of this manuscript.
Literature review process
The MEDLINE database was used to search the scientific
literature for current therapies related to MM and immunotherapy in humans and encompassed articles published
from 2012 to 2019, including clinical trials, meta-analyses,
practice guidelines and research in humans. The search
terms included ‘multiple myeloma’ AND ‘immunotherapy’, ‘daratumumab’, ‘elotuzumab’, ‘isatuximab’,
‘CAR T cell therapy’, ‘bispecific antibody’, ‘antibody-drug
conjugate’ and ‘quality of life.’ Articles were screened by
expert panel members to include only papers with clinically accurate and relevant information and to remove
duplicate articles from independent searches, resulting
in a final citation list cataloged using EndNote X9. The
citation list was supplemented with additional articles
identified by the panel, as appropriate and necessary for
a comprehensive literature review.

Daratumumab
The integration of effective mAbs into the treatment of
patients with MM has been in clinical development for
>10 years.27 The anti-CD38 therapy dara is the first immunotherapeutic mAb to be clinically tested and to elicit
durable responses as a single agent. This reported efficacy,
in addition to its proven safety record and enhanced clinical benefit in combination with other antimyeloma therapies, has led to several FDA approvals for dara in treating
patients with MM. Such evidence, also demonstrating a
Shah N, et al. J Immunother Cancer 2020;8:e000734. doi:10.1136/jitc-2020-000734
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lack of overlapping toxicity, deep clinical response rates
and long durations of response, places dara in a crucial
position for the treatment of patients with MM in both
the first-line and the relapsed/refractory setting.
Relapsed/Refractory setting
The phase III POLLUX study investigated dara plus lenalidomide and dexamethasone (D-Rd) versus Rd alone in
relapsed or refractory multiple myeloma (RRMM). The
dara regimen reduced the risk of disease progression or
death by 63% and significantly increased overall response
rate (ORR) in patients with RRMM compared with
Rd alone (93% vs 76%; p<0.001). Furthermore, when
combined with standard-of-care regimens across multiple
phase III studies including POLLUX and CASTOR (bortezomib+dexamethasone±dara), the addition of dara led
to ≥50% reductions in the risk of progression or death,
doubled complete response (CR) rates and tripled MRD-
negative rates at the 10-5 sensitivity threshold in patients
with RRMM.28–30 A 4-year follow-up analysis of POLLUX
examined 569 randomized patients (D-Rd, n=286; Rd,
n=283). At a median follow-
up of 51.3 months, D-
Rd
significantly prolonged progression-
free survival (PFS)
versus Rd (median 45.8 vs 17.5 months; HR 0.43; 95% CI
0.35 to 0.54; p<0.0001).31 A PFS benefit for D-Rd versus
Rd was also observed regardless of cytogenetic risk status.
In the phase III CASTOR trial evaluating dara in combination with bortezomib and dexamethasone (D-
Vd)
compared with Vd alone, the 12-month rate of PFS was
60.7% in the dara group vs 26.9% in the control group.
Additionally, the ORR was higher in the dara group than
the control group (82.9% vs 63.2%).32
The open-
label, multicenter phase Ib EQUULEUS
study (NCT01998971) evaluated dara in combination
with various backbone regimens in patients with newly
diagnosed MM as well as patients who had received prior
therapy. In the dara plus pomalidomide and dexamethasone (D-Pd) treatment arm (n=103), only patients who
had previous treatment were included (median number
of prior therapies=4, range=1–13), all of whom had
previous lenalidomide therapy. The ORR was 60% (95%
CI 50.1 to 69.7) with 17 patients achieving CR or better
and 5 (29%) of those patients achieving MRD negativity
at the 10-5 threshold. Median PFS was 8.8 months (95% CI
4.6 to 15.4), and the 12-month PFS rate was 42% (95%
CI 31.5 to 51.9). In exploratory analysis, PFS and ORRs
were similar across patients with standard or high cytogenetic risk.33 Based on data from the EQUULEUS study,
the FDA approved D-Pd for the treatment of patients
with MM who have received at least two prior therapies
including lenalidomide and a PI in 2017.
Significant PFS benefit was demonstrated for the
addition of dara to carfilzomib and dexamethasone
(KdD) for the treatment of patients with RRMM with
measurable disease who had received one to three prior
lines of therapy in the randomized, open-label, phase
III CANDOR study (NCT03158688). After a median
follow-up of 16.9 months and 16.3 months for the KdD
Shah N, et al. J Immunother Cancer 2020;8:e000734. doi:10.1136/jitc-2020-000734

and Kd arms, median PFS was not reached for the KdD
arm vs 15.8 months for the control arm (HR 0.63; 95% CI
0.46 to 0.85; p=0.0014). The ORR was 84.3% vs 74.7%
(p=0.0040), for KdD versus control, respectively, and the
rate of CR or better was 28.5% vs 10.4% with an MRD-
negative CR rate at 12 months of 12.5% for KdD vs 1.3%
for Kd (p<0.0001).34
Frontline daratumumab
Transplant-eligible patients
In an ongoing phase II, randomized study, the GRIFFIN
trial (NCT02874742) compared the combination of
dara, bortezomib, lenalidomide and dexamethasone
(D-VRd) with VRD in 207 patients with newly diagnosed
myeloma eligible for autologous HSCT. Patients received
four induction cycles of D-VRd (or VRD) every 21 days
followed by stem cell mobilization, high-
dose therapy,
and HSCT; two consolidation cycles of D-VRd (or VRD);
and maintenance therapy with dara and lenalidomide
(or lenalidomide alone) for 24 months.35 At primary
end point analysis, by the end of consolidation (cycle
6), the study met its prespecified one-sided alpha of 0.1
with a stringent complete response (sCR) rate of 42.4%
for patients receiving D-VRd vs 32% in the VRD arm.
Responses have continued to deepen throughout maintenance—rates of sCR improved for D-RVd versus RVd
(62.6% vs 45.4%; p=0.0177), as did rates of MRD negativity at the 10−5 threshold (51.0% vs 20.4%; p<0.0001).36
Overall, the regimen with dara (D-VRd) was found to be
safe and more effective than VRd alone, with an increase
in any-grade infection rates of 91% vs 62%, largely due
to grade 1/2 upper respiratory tract infections. Stem cell
yield was adequate in both arms. At a median follow-up of
22.1 months, the 24-month PFS rate was 95.8% vs 89.8%,
VRd combination.37 Survival data have
favoring the D-
not yet matured at the time of this publication. A phase
III study (PERSEUS) is ongoing to evaluate VRD versus
D-VRD.38
Data from the phase III CASSIOPEIA trial39 of 1085
patients showed that incorporating dara into a regimen
of bortezomib, thalidomide and dexamethasone (D-VTd)
led to a 34% reduction in disease progression risk
compared with the standard triplet therapy (VTd). The
trial was divided into two parts, an induction and consolidation phase followed by maintenance treatment with
dara or observation. In the induction phase, the addition
of dara was associated with a 53% reduction in the risk of
progression or death. At day 100 after transplantation, CR
or better was observed in 39% of the patients in the dara-
treatment group, with 64% achieving MRD-negativity, vs
26% and 44%, respectively, for those treated with VTd
alone.40 With a median follow-up of 18.8 months, the
estimated 18-
month PFS rate was 93% D-
VTd vs 85%
VTd (HR 0.47; 95% CI 0.33 to 0.67; p<0.0001). Based on
data from CASSIOPEIA, in September, 2019, the FDA
approved D-VTd in newly diagnosed transplant-eligible
patients.
3
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Transplant-ineligible patients
The MAIA trial (NCT02252172) investigated the clinical benefit of adding dara to lenalidomide and dexamethasone (D-Rd) as part of a phase III, randomized
trial in patients with transplant-
ineligible untreated
MM. The primary endpoint examined was PFS. At
median follow-up of 28.0 months, of the 737 randomized patients, disease progression or death occurred in
26.4% of patients in the dara group and 38.8% in the
control group. The estimated percentage of patients who
were alive without disease progression at 30 months was
70.6% (95% CI 65.0 to 75.4) and 55.6% (95% CI 49.5 to
61.3) in the dara and control groups, respectively (HR
0.56; 95% CI 0.43 to 0.73; p<0.001). The rates of CR or
better were 47.6% and 24.9% in the dara and control
groups (p<0.001), respectively. A total of 24.2% vs 7.3%
of patients in the dara and control groups, respectively,
reported results below the threshold for MRD (one
tumor cell per 105 total bone marrow cells) (p<0.001).41
Results from this study further support the use of dara
in combination with standard therapies in first-line treatment of patients with MM.
The ALCYONE trial (NCT02195479) assessed the
addition of dara to the combination of bortezomib,
VMP) in patients with
melphalan and prednisone (D-
treatment-naïve MM who are ineligible for HSCT in a
phase III, randomized study.7 In this study, 706 patients
received nine cycles of VMP either alone or with dara
until disease progression. The primary endpoint was
PFS. At a median follow-up of 40.8 months, the median
PFS was 36.4 months with D-VMP vs 19.3 months in the
control group (HR for disease progression or death 0.55;
95% CI 0.43 to 0.71; p<0.0001). The estimated 36-month
overall survival (OS) rate was 78% with D-VMP vs 68%
with VMP, with a significant benefit for OS observed for
D-VMP versus VMP alone (HR 0.60; 95% CI 0.46 to 0.80;
p=0.0003).42
Other combination trials
An ongoing phase II trial (NCT03012880) is investigating
the addition of dara to the triplet induction therapy of
ixazomib, lenalidomide, and dexamethasone (IRd) to
determine if the quadruplet regimen elicits enhanced
efficacy with a feasible schedule. Patients with previously
untreated MM were enrolled irrespective of their transplant eligibility and CR rate was the primary endpoint.
Treatment consisted of ixazomib 4 mg (days 1, 8, 15),
lenalidomide 25 mg (days 1–21), dexamethasone 40 mg
weekly and dara 16 mg/kg weekly for two cycles, every
other week during cycles 3–6, and then every 4 weeks
thereafter. As of the final assessment, all patients were
alive and progression-free with a median follow-up of 5.2
months (median five cycles, range 2–13). One patient
discontinued for alternate therapy. Responses proved
rapid with a 90% partial response (PR) or better (32%
very good partial response (VGPR)) after two cycles,
and 100% PR or better (50% VGPR) for 32 patients
who completed four cycles. The overall best confirmed
4

response rate among the 38 analyzed patients was 95%,
including 11% CR and 47% VGPR.43
Panel recommendations
Dara is FDA-approved and the panel recommends its use
in the following settings:
►► In combination with lenalidomide and dexamethasone (D-Rd) in newly diagnosed patients who are
ineligible for autologous stem cell transplant and in
patients with RRMM who have received at least one
prior therapy.
►► In combination with bortezomib, melphalan, and
prednisone (D-VMP) in newly diagnosed patients who
are ineligible for autologous stem cell transplant.
►► In combination with bortezomib, thalidomide, and
dexamethasone (D-VTd) in newly diagnosed patients
who are eligible for autologous stem cell transplant.
►► In combination with bortezomib and dexamethasone
(D-
Vd) in patients who have received at least one
prior therapy.
►► In combination with pomalidomide and dexamethasone (D-Pd) in patients who have received at least two
prior therapies including lenalidomide and a PI.
►► As monotherapy, in patients who have received at
least three prior lines of therapy including a PI and
an IMiD or who are double-refractory to a PI and an
IMiD.
Other combinations in newly diagnosed patients:
37
►► Based on emerging data (e.g. from the Griffin trial ),
the panel was comfortable recommending D-VRd as
one possible induction regimen option in newly diagnosed patients who are eligible for autologous stem
cell transplant.
►► A consensus could not be reached regarding the use
of dara in combination with carfilzomib, lenalidomide and dexamethasone (D-
KRd) in newly diagnosed patients who are eligible for autologous stem
cell transplant.
Other combinations in RRMM:
►► KdD is recommended for patients with RRMM in the
USA that are refractory to immunomodulatory drugs
and bortezomib, based on emerging data from the
CANDOR trial.34
Cytogenetic risk status
In both the CASTOR and POLLUX trials, dara combinations improved PFS regardless of the cytogenetic risk
status.28 30 The antibody combination regimens seem to
offer more benefit to the high-risk patients relative to the
doublet-based regimens in RRMM in these studies.29 In
the phase III MAIA trial of newly diagnosed patients, the
benefit of adding dara was more pronounced in the standard risk patients than the high-risk patients.41 However,
no tests for interaction between cytogenetic risk and PFS
were reported. Additionally, the subgroups with high-risk
cytogenetics are relatively small (92 patients in MAIA, 168
patients in CASSIOPEIA), and power for comparison of
PFS within these groups is not reported. At this juncture,
Shah N, et al. J Immunother Cancer 2020;8:e000734. doi:10.1136/jitc-2020-000734
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the data remain inconclusive on benefit from the addition of dara in the newly diagnosed induction setting for
patients with high-risk disease.
Panel recommendations
Until further phase III data become available, a
consensus could not be reached to recommend that
dara is the definitive choice for patients with high-risk
cytogenetics, particularly in the frontline setting.

►►

Dosing and administration
The dara package insert advises standard treatment with
steroids, acetaminophen and antihistamines 1–3 hours
prior to infusion to manage infusion-related reactions
(IRRs).10 Across trials, the vast majority of IRRs occurred
during the first dose.32 44 Additionally, a multicenter,
open-label early access treatment protocol study found
that IRR rate was one-third lower in patients who received
10 mg of the leukotriene receptor antagonist montelukast
30 min prior to dara dosing.45
Panel recommendations
Standard premedications as suggested below may be
used to mitigate IRRs:
–– Dexamethasone, 20 mg intravenous (IV) (for
dara monotherapy methylprednisolone, 100 mg is
preferred).
–– Acetaminophen, 650–1000 mg oral.
–– Diphenhydramine, 25–50 mg oral or IV.
–– Montelukast, 10 mg, orally dissolving tablet (ODT)
preferred, prior to first infusion.
►► After cycle 2, steroids may be omitted if the patient
has tolerated dara without IRRs.
►► For patients with severe IRRs during dose or a
history of respiratory comorbidities, oral corticosteroids (≤20 mg methylprednisolone or equivalent
intermediate-
acting or long-
acting corticosteroid)
should be administered per the prescribing label on
each of the 2 days following dara infusions.
►► Short-
acting and long-
acting bronchodilators and
inhaled corticosteroids may be considered for patients
with a long history of chronic obstructive pulmonary
disease (COPD).
►►

Subcutaneous dosing
The PAVO trial (MMY1004), an open-label dose-escalation
phase Ib study, evaluated subcutaneous delivery of dara
in patients with RRMM. Results suggested that dara can
be administered safely in a short time (3–5 min) as a
subcutaneous formulation with lower rates of IRRs, yet
retaining efficacy.46 An ongoing phase III randomized
multicenter study of subcutaneous versus IV administration of dara in patients with RRMM, the COLUMBA trial
(NCT03277105), supports use of flat-dose 1800 mg dara
subcutaneously. A total of 522 patients who had received
a median of 4 prior lines of therapy including PIs and
IMiDs were randomized to receive dara subcutaneously
(n=263) or IV dara (n=259). The rates of all grade IRRs
were 34.5% vs 12.7%, respectively and responses, median
Shah N, et al. J Immunother Cancer 2020;8:e000734. doi:10.1136/jitc-2020-000734

PFS and 6-
month OS rates were comparable between
both groups.47 Subcutaneous injection was non-inferior
to IV dara across all body-weight subgroups, with subcutaneous being associated with lower rate of IRRs.48 Importantly, patients also reported improved experience with
subcutaneous dara, based on shorter administration
time.49 The phase II, open-label, multicenter PLEAIDES
trial (NCT03412565) confirmed the safety profile of
subcutaneous dara in combination with standard regimens such as VRd, Rd, or VMP in both the first-line and
RR settings. Across groups, ORRs with subcutaneous
dara- containing regimens were similar to those reported
in IV dara trials (i.e. GRIFFIN for D-VRd, POLLUX for
D-RD, ALCYONE for D-VMP). Importantly, the rate of
IRRs across all cohorts receiving subcutaneous dara was
7.5% (15/199), with the majority (93.3%) being grade
1–2.50 Based on results from COLUMBA and PLEAIDES,
the FDA approved subcutaneous dara on May 1, 2020.
Panel recommendation
The panel felt that the new subcutaneous formulation
will provide a convenient option for patients.

►►

Split dosing
Given that dara is only stable for 16 hours after reconstitution, the first dose of 16 mg/kg IV, with a median
infusion time of 6–8 hours may result in drug remaining
at the close of the infusion center that cannot be saved
until the next day. Of note, stability data allow dara to be
reconstituted in 4 mg/mL, thereby allowing volumes to
be reduced.51
Panel recommendations
For infusion centers with limited hours of operation,
the first dose of dara can be split as 8 mg/kg across
2 days, which has a median infusion time of approximately 4 hours on each day. Nearly all IRRs occur on
the first dose.
►► For dose 4 and beyond, dara can be given safely over
90 min.52
►► Once subcutaneous dara is commercially available,
the need to split dose will diminish.
►►

Special considerations
Patients with severe renal insufficiency, defined as glomerular filtration rate <30, are typically excluded from clinical trials despite accounting for about 20% of patients
with MM.53 However, anti-CD38 antibodies are not metabolized by the kidney, and there are case reports of patients
being safely treated in the setting of severe renal insufficiency.54 55
Hepatitis B virus (HBV) reactivation carries significant
risk of morbidity and mortality for patients receiving
immune-
modulatory and biological therapies. A large
reservoir of individuals at risk for reactivation exists
within the general population, including people currently
infected and those with prior exposure.56 Both the American Society of Clinical Oncology (ASCO) and the American Gastrological Association guidelines recommend all
5
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patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved
HBV infection by blood tests for hepatitis B surface
antigen (HepBsAg) and antibody to hepatitis B core
antigen (HepBcAb).57 58 Two options exist for patients
with evidence of prior exposure: serial monitoring for
HBV DNA by PCR or initiation of prophylactic antivirals for patients deemed to be at high risk, such as those
receiving biologics, high-dose chemotherapy or stem cell
transplants.

trough levels better than 8-
week intervals. Trials are
ongoing investigating dara as maintenance therapy after
autologous stem cell transplant (NCT03901963 and
NCT03346135).67 There is insufficient data to establish
efficacy for retreatment with dara. However, a retrospective study of 34 patients with RRMM found that
one third of patients refractory to both dara and pomalidomide responded when they were retreated with the
combination.68

Panel recommendations
►► Although patients with renal failure, patients with
COPD and patients with plasma cell leukemia are
commonly excluded from clinical trials, the panel felt
that these populations may safely be treated with dara.
►► Before administering dara, patients should be tested
for hepatitis B, given the potential risk of viral
reactivation.
►► For patients with no known hepatitis B exposure history, serum tests should be performed for
HepBcAb, HepBsAb, and HepBsAg. In cases with
evidence of hepatitis B exposure, a PCR test for hepatitis B genomes is recommended. For patients with
positive serum tests for HepBcAb, entacavir should be
considered.
►► Prophylactic acyclovir should be administered to
patients receiving dara.

►►

Response evaluation, treatment duration
Because dara can render myeloma plasma cells CD38
negative by flow cytometry, treatment can hinder the
ability to accurately ascertain MRD. Alternatives include
evaluating for MRD by NGS or alternative anti-CD38 antibodies, such as vs38.59 60 Additionally, the Hydrashift 2/4
dara is an FDA-approved assay to mitigate antibody interference.61 Antibody interference testing is unnecessary
for non-IgG kappa isotype patients, patients with detectable disease by free light chain (FLC) or Bence Jones
protein (BJP), or patients with an M-spike >0.2 g/dL by
serum protein electrophoresis (SPEP).62–64
Anti-CD38 antibodies such as dara interfere with blood
bank testing by binding to CD38 on red blood cells (RBCs)
and causing panagglutination on the indirect antiglobulin test.65 Because many patients with MM have received
multiple transfusions in the context of treatment and
may in fact have RBC alloantibodies, a false-positive result
should not be assumed solely on the basis of dara exposure. The most common and widely validated method
of interrupting anti-CD38 antibody binding to RBCs is
to treat with the reducing agent dithiothreitol (DTT).66
Importantly, DTT has the potential to denature other
clinically significant antigens including Kell and Yt.65
All approved dara-containing regimens have used dara
until progression, which for patients reaching 7 months
and beyond is once monthly. Based on pharmacokinetic data, it appears that if dara is to be given as maintenance therapy, a 4-week schedule is likely to maintain
6

Panel recommendations
Response to dara should be monitored according to
institutional protocols, most of which assay MM labs
monthly. In patients with IgG kappa myeloma, serologic determination of CR can be confounded by the
presence of dara.
►► In the presence of a measurable M-
spike, dara will
have a minimal effect on disease measurement. When
patients reach undetectable levels, however, mass
spectrometry or other antibody interference testing
methods should be considered.
►► A consensus could not be reached to recommend
retreatment with dara in patients relapsing on
monthly dosing.
►► Patients on dara should receive seasonal influenza
vaccines.
►► To manage infections following treatment, intravenous IgG (IVIG) should be administered according
to established institutional criteria, which are not
specific to dara.
Elotuzumab
Elotuzumab is a mAb targeting signaling lymphocytic activation molecule F7 (SLAMF7) that elicits its antitumor
effect through both direct activation of natural killer
(NK) cells and antibody-
dependent cellular toxicity.69
Elotuzumab was first approved for MM on November
30, 2015.70 Although no studies have found benefit for
elotuzumab monotherapy, either in the advanced71 or
smoldering72 settings, it has demonstrated significant
activity in combination with IMiDs and other agents in
the relapsed and refractory setting.73 At the time of publication, elotuzumab has received FDA approval as combination therapy with lenalidomide and dexamethasone
(E-Rd) for the treatment of adult patients with RRMM
who have received one to three prior therapies or in
combination with pomalidomide and dexamethasone
(E-Pd) for adult patients who have received at least two
prior therapies including lenalidomide and a PI.11
Literature review
The ELOQUENT-2 trial (NCT01239797) was a phase III,
randomized, open-label study that evaluated the efficacy
and safety of E-Rd versus Rd alone in patients with MM
who had received one to three prior lines of treatment
and had documented disease progression after their most
recent therapy. During the trial, 646 patients were randomized to E-Rd (n=321) or Rd (n=325), and in an extended
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5-
year follow-
up, the longest median follow-
up of any
immuno-oncology agent in MM, 27% reduction in risk of
progression or death was attained for E-Rd versus Rd (HR
0.73; 95% CI 0.60 to 0.87). The ORR was 79% (E-Rd) vs
66% (Rd).74 Approximately 32% of patients had del(17)p
and 9% of patients had t(4;14), and the outcomes in high-
risk patients were comparable with those of the patients
at standard risk.75 The most common grade 3–4 adverse
events (AEs) with E-Rd versus Rd were infections (35%
vs 27%), neutropenia (26% vs 34%), anemia (17% vs
17%) and fatigue (10% vs 9%). Discontinuation of study
regimens was mostly due to disease progression (55% vs
56% at the 5-year mark). Thus, E-Rd showed an overall
sustained, durable improvement in PFS, reporting a 27%
reduction in the risk of progression or death.74
Based on the results from ELOQUENT-2, ELOQUENT-3
(NCT02654132) was initiated as a phase II, randomized,
open-label trial investigating the addition of elotuzumab
to pomalidomide plus dexamethasone (E-Pd vs Pd). The
combination of pomalidomide and dexamethasone has
previously been shown to be effective in patients with MM
refractory to lenalidomide and a PI.76 In ELOQUENT-3,
a total of 117 patients were randomly assigned to
receive either E-Pd (60 patients) or Pd alone (control;
57 patients) with the primary end point of investigator-
assessed PFS.77 After a minimum follow-up period of 9.1
months, median PFS was 10.3 months in the E-Pd group
vs 4.7 months in the control group (HR 0.54; 95% CI 0.34
to 0.86; p=0.008), and ORR was 53% vs 26%, respectively
(OR 3.25; 95% CI 1.49 to 7.11). Benefit from E-Pd was
also demonstrated in patients who had received at least
four previous lines of therapy, with a median PFS of 10.3
months (95% CI 3.7 to not reached) in the E-Pd group
and 4.3 months (95% CI 1.9 to 9.3) in the control group
(HR 0.51; 95% CI 0.24 to 1.08). The safety of E-Pd was
notable, with grade 3/4 neutropenia occurring in 13%
in E-Pd vs 27% for Pd and grade 3/4 infections occurring
in 13% vs 22%. The main reason for discontinuation of
the trial treatment was disease progression (43% of the
treated patients in the E-Pd group and 56% of the treated
patients in the control group).77
A phase II trial (NCT01478048) evaluated the addition
of elotuzumab to the combination of bortezomib and
dexamethasone (Vd) in patients with MM with documented disease progression after one to three prior lines
of therapy. The 1-year PFS rate was 39% (95% CI 28%
to 50%) with E-Vd vs 33% (95% CI 22% to 44%) with
Vd, yielding a 28% reduction in the risk of progression
or death with E-Vd compared with Vd. Follow-up analysis at the 2-year point revealed more striking differences
between subgroups stratified by FcγRIIIa V genotype,
with a median PFS of 22.3 months for patients in the
E-Vd group who were homozygous for the high-affinity
FcγRIIIa V (VV) allele (13 patients) compared with 9.8
months in patients in the E-Vd group homozygous for the
low-affinity FcγRIIIa F (FF) allele (24 patients) and a sizeable improvement over patients in the Vd group homozygous for the V allele (8.2 months). A trend toward longer
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PFS with E-Vd was also observed across key subgroups,
including in patients aged 65 years or older and in those
who had received a prior PI or IMiD. Discontinuation in
the overall population was mostly due to disease progression (57%). An increased rate of infections was observed
for elotuzumab in combination with a PI: 67% vs 53% of
all grade and 21% vs 13% of grade 3/4 for E-Vd versus Vd,
respectively.78
Elotuzumab has also been studied in combination with
thalidomide and low-dose dexamethasone in a phase II
single-arm safety study in the relapsed/refractory setting,
where minimal toxicity was observed with the triple
regimen and efficacy data suggested potential clinical
benefit in a highly pretreated population. In the trial,
grade 3 or higher non-hematological AEs were reported
in 63% of patients, most commonly asthenia (35%) and
peripheral edema (25%), and six patients (15%) had an
infusion reaction. The ORR was 38%, with median PFS
3.9 months and median OS 16.3 months.79 Another phase
II trial (NCT03155100) evaluating the combination of
elotuzumab, carfilzomib, pomalidomide and dexamethasone in RRMM is actively recruiting.
Patient selection
As of 2019, two phase III trials were exploring elotuzumab-
containing regimens as a frontline option. ELOQUENT-1
(NCT01335399) is investigating the addition of E-Rd to
treat newly diagnosed, non-transplant eligible MM.80 The
phase III GMMG-
HD6 trial (NCT02495922) is investigating the efficacy of elotuzumab in combination with VRd
induction/consolidation and lenalidomide maintenance
in transplant-eligible patients as frontline therapy.81 Additionally, SWOG S1211 (NCT01668719) is a phase I/II
trial evaluating for the first time a four-drug E-VRd induction regimen in high-risk newly diagnosed MM. Phase I
has been completed and of the eight patients enrolled,
the most common AEs were fatigue (100%), peripheral
sensory neuropathy (83%), edema (83%), lymphopenia
(66%) and leukopenia (50%), with one dose-
limiting
toxicity (grade 4 lymphopenia) observed.82 E-Rd is also
being evaluated in patients with high-
risk smoldering
multiple myeloma (SMM). In a phase II trial, of the 34
evaluable patients enrolled to both arms of the study,
the clinical benefit rate was 97% with an ORR of 71%,
including 9 very good VGPRs (26%) and 15 PRs (44%)
and at the 1-year mark, no patients progressed to active
disease during, or after, protocol therapy.83
No randomized studies have directly compared combination therapy with anti-CD38 antibodies (eg, dara and
isatuximab) to elotuzumab-containing regimens. Given
the temporary depletion of NK cells with anti-
CD38
monoclonal antibodies, treatment with elotuzumab-
containing (which may be dependent on NK cell function) regimens in the immediate next line of therapy has
not been formally studied in prospective studies. The
Monoclonal Antibodies in Multiple Myeloma: Outcomes
after Therapy Failure study evaluated 275 patients with
anti-CD38 refractory MM and found that the addition
7
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of elotuzumab had an ORR of 21% with median PFS 2.6
months and OS 8.3 months.84 A retrospective analysis of
50 heavily pretreated patients who received both elotuzumab and dara found that responses to elotuzumab
decreased when given after dara, but responses to dara
did not change regardless of the treatment sequence.
No statistical difference was seen in ORR (78% for elotuzumab vs 89% for dara) for the initial antibody given, but
a significant difference in ORR (61% for elotuzumab vs
88% for dara) was observed for the agent given second
(p=0.04).85 Another retrospective study that analyzed 86
patients who had progressed on elotuzumab in combination with an immunomodulatory drug reported a 35.6%
ORR on subsequent treatment with an anti-CD38 mAb
(dara or isatuximab) with a median PFS of 4.6 months
(95% CI 1.6 to 7.6) and median OS of 15.3 months
(95% CI 8.2 to 22.4).86 A small retrospective analysis of 37
patients found significantly higher ORR and cumulative
PFS for elotuzumab prior to dara (64.3% and 22.67%)
compared with dara before elotuzumab ((34.8% and
10.5%).87 It is important to note, however, the clear selection biases in analysis of real-world patients treated with
an agent without single agent activity.

infusion of elotuzumab administered over 1 hour from the
third dose onward.88 ELOQUENT-2 and ELOQUENT-3
both gave elotuzumab at 10 mg/kg intravenous weekly
for the first 8 weeks. However, in ELOQUENT-2, 10 mg/
kg was continued every 2 weeks for cycles 3 and beyond
whereas in ELOQUENT-3, elotuzumab was given 20 mg/
kg intravenous every 4 weeks for cycle 3 and beyond.
Similar to other therapeutic antibodies, elotuzumab
may interfere with protein electrophoresis or immunofixation measurements,89 causing false positives for
M-spike results in the peripheral blood and potentially
affecting the assessment of response according to the
International Myeloma Working Group (IMWG) criteria.
Unlike with dara, gel-shift approaches have not yet been
developed to eliminate false positives for elotuzumab.
Possible workaround options for the measurement of
elotuzumab-induced M-spikes or imunofixation electrophoresis include the SLAMF790 or mass spectrometry-
based approaches.62 63

Panel recommendations
E-Rd is approved in patients who have received one to
three prior therapies.
►► E-Pd is approved in patients who have received at least
two prior therapies.
►► Patients with high-risk cytogenetics may benefit from
elotuzumab.
►► At present, there is no approved indication for the use
of elotuzumab in the initial management of myeloma.
►► By consensus, elotuzumab-
containing regimens may
be considered for patients who have progressed on
dara-containing regimens.
►► Elotuzumab should not be used as a single agent.
►► Prior treatment with elotuzumab is not a contraindication for treatment with anti-CD38 antibodies.
►► By consensus, elotuzumab-
containing regimens are
not recommended for patients with a rapidly growing
disease burden.

Panel recommendations
In published trials, infusion-related reactions (IRRs)
have been most prevalent with the first infusion.
►► The first dose of elotuzumab should start at 0.5 mL/
min for the first 30 min, then 1 mL/min. The second
dose should start at 3 mL/min for 30 min, then 4 mL/
min and from the third dose on, the infusion can be
given at 5 mL/min.
►► Per prescribing information, patients should be
premedicated 45–90 min prior to infusion with dexamethasone 8 mg, an H1 and H2 blocker and acetaminophen (650–1000 mg orally).
►► For the most part, myeloma-
specific immune
responses should be measured with each cycle as per
normal practice.
►► In patients with IgG kappa myeloma, determination
of CR can be confounded by elotuzumab.
►► In the presence of a measurable M-spike, elotuzumab
will have a minimal effect on disease measurement.
When patients reach undetectable levels, however,
mass spectrometry or other antibody-
interference
testing methods should be considered.

Administration, dosing, and monitoring
In the ELOQUENT-2 trial, IRRs were reported in 33
patients (10%) in the elotuzumab arm, with mostly grade
1/2 IRRs and no grade 4 or 5 events. The majority of
IRRs occurred during the first infusion.75 The prescribing
information for elotuzumab recommends the premedication regimen developed during ELOQUENT-2: oral
dexamethasone 28 mg 3–24 hours prior to each elotuzumab infusion and then an additional 8 mg administered intravenously 30–90 min before the infusion along
with diphenhydramine (25–50 mg), ranitidine (50 mg)
and acetaminophen (650–1000 mg).11 75 The prescribing
information states that the infusion rate may be increased
to 5 mL/min after four treatment cycles, however a phase
II safety study found no increase in AEs with a faster

Other considerations
In the ELOQUENT-2 trial, serious AEs were reported
in 65% and 57% of patients in the elotuzumab group
and the control group, respectively75 and the incidence
of serious AEs was 53% in the elotuzumab group and
55% in the control group, respectively during the
ELOQUENT-3 study.77 The rates of anemia, neutropenia and thrombocytopenia were similar between
the elotuzumab and control groups in both studies. In
the ELOQUENT-2 trial, the incidence of grade 3 or 4
lymphocytopenia was significantly higher in the elotuzumab arm (77% vs 49%), however the rates were much
lower and not significantly different between treatment
arms during ELOQUENT-3 (8% vs 2%).75 77 Overall
infection rates did not increase with the addition of

►►
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elotuzumab in the ELOQUENT-2 or ELOQUENT-3
trials.75 77 However, increased incidence of herpes zoster
infections was noted in the elotuzumab groups in both
studies (4.1% vs 2.2% and 5% vs 2%).91
Although the ELOQUENT-2 and ELOQUENT-3 trials
excluded patients in renal failure, a phase Ib study of
E-Rd in 26 patients with MM and various levels of renal
impairment did not observe any statistically significant
differences in maximum observed serum concentration,
nor areas under the concentration-time curves between
the groups with severe renal impairment (creatinine
clearance (CrCl) <30 mL/min) and end-
stage renal
disease (requiring dialysis) compared with patients with
normal renal function (CrCl ≥90 mL/min).92 One case
report described fatal renal failure in a man aged 61 years
with IgG kappa MM who developed tumor lysis syndrome
1 week after elotuzumab treatment,93 but this has not
been reported in any large clinical trials.
Panel recommendations
Although patients with renal impairment were
excluded from clinical trials, the panel felt that elotuzumab may be used in patients with severe renal insufficiency (CrCL <30 mL/min).
►► A consensus could not be reached to recommend
using elotuzumab in patients with hepatic impairment or plasma cell leukemia.
►► Antiviral prophylaxis is recommended for patients
receiving elotuzumab.
►► To manage infections following treatment, IVIG
should be administered according to established
institutional criteria, which are not specific to
elotuzumab.
►► At this time, no biomarkers of response or resistance
to elotuzumab are known.
►►

Isatuximab
Isatuximab is a mAb that targets a distinct epitope on
the plasma cell surface marker CD38, which promotes
tumor cell killing through classic Fc-dependent immune-
effector mechanisms, antibody-dependent cellular cytotoxicity, complement-dependent cellular cytotoxicity, and
antibody-
dependent cellular phagocytosis.94 Similar to
dara, isatuximab has been shown to exhibit immunomodulatory effects in preclinical models through reducing the
numbers of regulatory T cells (Tregs) as well as decreasing
immune inhibitory cytokine production, including interleukin (IL)-10. Unlike dara, isatuximab was selected
based on its ability to directly trigger MM cell death in
the absence of cross-linking agents and independently of
effector cells . In 2020, isatuximab was approved by the
FDA in combination with pomalidomide and dexamethasone (I-Pd) for adult patients with MM who have received
at least two prior therapies including lenalidomide and a
PI based on results from the multicenter, multinational,
randomized, open-label, two-arm, phase III ICARIA-MM
study.
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Literature review
Isatuximab is currently being evaluated in multiple
ongoing phase III clinical trials in combination with
current standard treatments for people with both RRMM
naïve MM. In the relapsed refractory
and treatment-
setting, based on promising results from a phase Ib study
where isatuximab combined with carfilzomib led to an
ORR of 61% and a clinical benefit rate of 86%, the ongoing
IKEMA study (NCT03275285) recruited 302 participants
with RRMM to assess the clinical benefit of isatuximab
combined with carfilzomib and dexamethasone (I-Kd)
versus Kd alone.95 In 2019, initial positive results from
the randomized phase III ICARIA-MM (NCT02990338)
trial96 were presented at the ASCO Annual Meeting and
the European Society of Hematology Annual Meeting,
reporting benefits for I-Pd in RRMM. The trial found that
I-Pd prolonged PFS by 5 months compared with Pd alone
(HR 0.596; 11.53 vs 6.47 months; 95% CI 0.44 to 0.81,
p=0.001) and ORR was also significantly greater with I-Pd
compared with Pd (60% vs 35%; p<0.0001), similar to the
results observed in the phase Ib study that preceded this
trial.97 The triplet regimen also demonstrated a significantly higher VGPR rate and a longer duration of response
compared with Pd (31.8% vs 8.5%; p<0.0001 and median
13.27 vs 11.07 months, respectively). Among patients who
achieved a response, I-Pd demonstrated faster median
time to first response compared with Pd alone (35 vs 58
days). Moreover, time to next treatment was longer with
I-Pd compared with Pd alone (HR 0.538; median not
reached vs 9.1 months).98 These results were the basis for
FDA approval of I-Pd for RRMM in 2020.
In patients with newly diagnosed MM, isatuximab is
being evaluated in combination with the standard of
care triplet regimen of VRd in multiple ongoing trials.
The phase III IMROZ trial (NCT03319667)99 randomized
475 patients with newly diagnosed MM to receive either
induction treatment with 4×6 week cycles with IV isatuximab+subcutaneous bortezomib+oral lenalidomide+IV or
oral dexamethasone followed by continuous treatment
with 4-
week cycles with IV isatuximab+oral lenalidomide+IV or oral dexamethasone, or a control regimen
of induction with VRd followed by continuous treatment
with Rd. The primary outcome measure will be PFS and
the estimated primary completion date is in December
2022. Another study evaluating the effect of isatuximab
in combination with RVd induction therapy, GMMG HD7
(NCT03617731), had recruited 662 patients with newly
diagnosed MM in 2019, and the trial will evaluate MRD
negativity as well as PFS as primary outcome measures.
Panel recommendations
I-Pd is approved and recommended by the panel for
patients with RRMM who have received more than
two prior lines of therapy.
►► Although patients with renal failure, patients with
COPD and patients with plasma cell leukemia were
excluded from initial clinical trials, these populations
may safely be treated with isatuximab.
►►
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Administration and dosing
In the phase Ib study of I-Rd, IRRs were observed in
83% of patients receiving isatuximab at an infusion rate
of 250 mg/hour, prompting the adoption of a 175 mg/
hour rate. The median durations for the first infusions
were 3.7 and 3.1 hours, with shorter times for the second
doses.100 Across multiple trials, IRRs most commonly
occurred during the first doses of isatuximab, and
were substantially less frequent on subsequent infusions.95 97 100
Panel recommendations
In accordance with published protocols, isatuximab
should be started at 175 mg/hour initial infusion rate
with a duration range of 2–7 hours.
►► Standard premedications are recommended up to
60 min prior to infusion to mitigate IRRs. Recommendations should be guided by label once approved by
regulatory agencies. A suggested example is as follows:
–– Dexamethasone 40 mg IV or methylprednisolone
100 mg IV.
–– Diphenhydramine 50 mg IV or equivalent.
–– Ranitidine 50 mg IV or equivalent.
–– Acetaminophen 650–1000 mg oral administration.
►► In patients with respiratory disease (eg, asthma or
reduced forced expiratory volume in 1 s), consider
adding an adrenergic bronchodilator (albuterol
inhaler/nebulizer) as premedication.
►►

Special considerations
Prior exposure to mAb therapies
No large, randomized studies have evaluated whether
prior exposure to mAbs alters efficacy of subsequent
lines of therapy directed against the same antigen in MM.
Dara has been demonstrated to reduce CD38 expression
on MM cells within hours of the first infusion in clinical
trials, yet some patients with reduced CD38 expression
achieved deep and durable responses with treatment.101
A case report has been published describing two partial
remissions in two relapsed patients after retreatment with
dara, and plasma cells from those patients did not display
decreased CD38 expression.102 More studies will need
to be done to determine if retargeting CD38 is a viable
option.
Panel recommendations
►► No consensus could be reached on using isatuximab
in patients who had progressed on a dara-containing
regimen.
Antibody interference in serum protein electrophoresis
Similar to dara, isatuximab may interfere with immunofixation results and appear as IgG kappa. Mass spectrometry, NGS or gel-shift approaches can help resolve
antibody interference on SPEP. Antibody interference
testing is unnecessary for non-IgG kappa isotype patients,
patients with detectable disease by FLC or BJP or patients
with an M-spike >0.2 g/dL by SPEP.62–64 89
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Panel recommendations
For most patients, the panel recommends antibody
interference testing by mass spectrometry for patients
treated with isatuximab.

►►

Infection care
The European Society of Clinical Microbiology and Infectious Disease Study Group for Infections in Compromised
Hosts concluded that, based on available evidence, CD38-
targeting therapies likely do not substantially increase
patients’ risk for bacterial infections.103 Results from trials
with dara suggest that patients on combination regimens
may be at elevated risk for varicella zoster virus infection
and cytomegalovirus (CMV) reactivation.103–105
Panel recommendations
Patients should receive seasonal influenza vaccines
while on isatuximab.
►► To manage infections following treatment, IVIG
should be administered according to established institutional criteria, which are not specific to isatuximab.
►►

Emerging therapies
Several promising new immunotherapy modalities are
currently being evaluated in clinical trials for newly diagnosed as well as RRMM. Strategies include mAbs, CAR
T cells, bispecific engagers of T cells, ADCs and cancer
vaccines. Although the products described in subsequent
sections have yet to be approved by the FDA at the time
of publication, it is important for the oncology community to be familiar with emerging therapies, for possible
consideration of referring their patients to an appropriate clinical trial or incorporating these new treatments
into clinical practice, when they become available. Even
though immune checkpoint inhibitors are FDA-approved
for other disease settings and have been studied both as
monotherapy and in combination with IMiDs for MM,
safety signals observed in early trials and lack of clear clinical benefit motivated the panel to refer readers elsewhere
for discussion of those agents.106 Given the rapid pace of
the field, therapies other than those described in this
manuscript may advance through clinical trials soon after
publication, and inclusion or absence of a specific agent
herein should not be interpreted as an endorsement.
Emerging therapies targeting BCMA
Both CD38 (the antigen targeted by dara and isatuximab) and SLAMF7 (elotuzumab) are expressed in
healthy tissues including hematopoietic lineages and
immune effector cells.107 108 B cell maturation antigen
(BCMA), by contrast, is a surface marker with highly
restricted expression that is very frequently upregulated
in MM cells. In healthy tissues, BCMA is only found on
late memory B cells committed to plasma cell differentiation, where it is required for the survival of long-lived
plasma cells.109 110 In MM, BCMA is associated with the
proliferation and survival of cancer cells, and it is associated with the induction of an immunosuppressive bone
marrow microenvironment.111 112 Membrane BCMA is
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cleaved by the enzyme gamma secretase,113 114 leading to
the formation of a soluble form (sBCMA), and elevated
levels of sBCMA in patient serum have been correlated
with disease status and poor prognosis.111 The administration of an oral gamma secretase inhibitor to patients
can significantly increase BCMA density on the surface of
malignant plasma cells and reduce sBCMA levels.114

CAR T cells
Escalating pipelines of BCMA-targeting CAR T therapies
for MM have posted encouraging results. In late 2019,
>40 trials investigating BCMA-targeting CAR T cells were
actively recruiting patients, with the majority in phase I
or phase I/II. Agents further along the path toward FDA
approval are bb2121 (idecabtage vicleucel),12 115 a second-
generation CAR containing a 4-1BB costimulatory motif,
which received Breakthrough Therapy designation in
2017,116 and JNJ-68284528 (also called JNJ-4528, formerly
LCAR-B38M), which binds to two distinct epitopes on
BCMA,117 118 and has also been granted Breakthrough
Therapy designation in addition to PRIME designation
by the European Medicines Agency (EMA). Additionally, under investigation are cell-based therapies using
NK cells119 as well as TCR-engineered T cells, such as the
enhanced affinity NY-ESO-1 TCR.120
Literature review
A phase I trial investigated the novel CAR T cell therapy,
bb2121, in patients with heavily pretreated RRMM. For
the first 33 consecutive patients who received a bb2121
infusion at the cut-off date of 6.2 months after last infusion, the ORR was 85% (95% CI 68.1 to 94.9), with 45%
of patients having a CR (9%) or stringent CR (sCR 36%),
respectively. Of the 15 patients with a CR, 6 relapsed.
The median PFS was 11.8 months (95% CI 6.2 to 17.8).
All 16 patients who had a response (PR or better) and
who could be evaluated for MRD achieved MRD-negative
status (≤10−4 nucleated cells). Successful expansion of
CAR T cells was associated with responses, during which
expanded cells persisted up to 1 year after the infusion.
Interestingly, response rates of 74% or higher were
observed among patients with progressive disease during
their most recent line of therapy, those who had received
dara as part of their most recent line, those who did not
receive bridging therapy and those who had extramedullary disease (plasmacytomas) at baseline.12 Hematological toxic effects were the most common AEs of grade
3 or higher, including neutropenia (85% of patients),
leukopenia (58%), anemia (45%) and thrombocytopenia
(45%). Twenty-five patients (76%) experienced cytokine
release syndrome (CRS) (grade 1–2 in 70% and grade 3 in
6% of patients). Neurological toxic effects occurred in 14
patients (42%) and were of grade 1–2 in 39% of patients.
One patient (3%) had a reversible grade 4 neurological
toxic effect.12
At the time of writing, several phase II trials are evaluating bb2121 in the RRMM setting, including KarMMa
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and KarMMa-2 (NCT03361748 and NCT03601078). The
KarMMa-1 trial has completed recruitment for patients
who have received at least three prior lines of therapy,
whereas the KarMMa-2 study is enrolling multiple cohorts
including subjects with ≥3 prior antimyeloma treatment
regimens, subjects with one prior antimyeloma therapy
including autologous stem cell transplantation (ASCT)
and with early relapse, subjects with one prior antimyeloma
therapy not including ASCT and with early relapse, and
subjects with inadequate response to ASCT during their
initial antimyeloma therapy. Additionally, a multicenter,
randomized, open-label, phase III study comparing the
efficacy and safety of bb2121 vs standard triplet regimens
in subjects with RRMM treated with two to four prior
lines of therapy, the KarMMa-3 trial (NCT03651128), is
ongoing. KarMMa-4, which is a phase I study with bb2121
to be given after four cycles of induction chemotherapy
in newly diagnosed, high-risk MM, has started recruiting
(NCT04196491).
The EVOLVE study is a phase I/II trial evaluating the
safety and efficacy of JCARH125, a fully human CAR, in
patients with RRMM (NCT0343001). In late 2019, 44
patients with highly refractory disease (median of nine
risk cytogenetics) had
prior therapies, 64% with high-
received various doses of JCARH125. Overall, an ORR
of 82% was achieved, with CR/sCR reported in 27% and
VGPR or better in 48% of patients with limited follow-up.
At the lowest dose of 50×106 total CAR T cells, the CR/sCR
reported was 43%, with a trend of deepening responses
over time. CRS was observed in 80% of patients, with 9%
having a grade ≥3 AE. Neurotoxicity occurred in 18% of
patients, with 7% reported to be grade ≥3. The product
received FDA orphan drug status in 2017.121
Another CAR T therapy in development is JNJ-4528
(identified as LCAR-B38M in China), which targets two
distinct epitopes of BCMA. In early results from the
LEGEND-2 phase I/II open study (NCT03090659) of 57
Chinese patients with RRMM treated with LCAR-B38M,
the ORR was 88% and the CR rate was 68%. CRS was seen
in 90% of patients, with 7% having grade 3 CRS. Only
one patient developed neurotoxicity.117 At data cut-off,
the OS rate at 18 months was 68% (range 54%–79%) with
median duration of response (mDOR) 22 months (range
13–29). At 18 months, the rate of PFS was 50% (range
36–63) for all treated patients and 71% (range 52–84)
for MRD-negative patients with CR. The median PFS for
all treated patients was 20 months (range 10–28) and 28
months (range 20–31) for MRD-negative patients with
CR. It is important to note that many therapies available
in the USA are not routinely available in China, and these
patients were significantly less heavily pretreated then the
patients on US trials.122 The phase Ib/II CARTITUDE-1
study (NCT03548207) is evaluating JNJ-4528 in the USA
and Europe, concomitantly with the ongoing phase II
CARTIFAN-1 trial (NCT03758417) in China.123 As of June
24, 2019, 25 patients had been infused with JNJ-4528 in
the phase Ib portion of the study. In an update presented
December 2019 at the American Society of Hematology
11
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annual meeting, 21 patients were evaluable for response
with a median follow-up of 3 months (range 1–10). Reduction in tumor burden was observed for all patients with
ORR of 91% including 4 sCRs, 2 CRs, 7 VGPRs and 6 PRs.
Of the 15 patients with evaluable bone marrow samples,
10 were MRD-negative at the 10−5 sensitivity level.124
P-BCMA-101, a novel BCMA-targeting CAR T produced
using the non-viral transposase-transposon piggyBac DNA
Modification System,125 has entered phase II testing. In
a phase I trial with 11 patients, encouraging safety data
was reported with only 1 case of suspected CRS that was
minimal and short-lived. PR or better was obtained in 7
out of 10 patients. The manufacturing technology results
in CAR T cell products with a high percentage of self-
renewing, long-lived stem cell memory T cells due to the
introduction of a selection gene along with the CAR.
Second, the use of the protein Centyrin binder instead
of a traditional antibody-based binder may yield a potentially less immunogenic product. Additionally, the small
size of the Centyrin binder has allowed P-BCMA-101 cells
to be engineered with a ‘safety switch’ gene to allow the
cells to be eliminated if desired. The product received
FDA RMAT designation in 2018 and orphan drug status
in 2019.126
Early promise has also been demonstrated through
the combination of BCMA CAR T cells and an oral
gamma secretase inhibitor (GSI; JSMD194) designed
to increase surface density of the BCMA target. Among
the eight patients reported to date on this phase I trial
(NCT03502577), a median 20-
fold increase in BCMA
surface density was observed following three doses of
the oral GSI, and although the data are not mature,
an ORR of 100% was noted among evaluable patients,
including those treated at the lowest BCMA CAR T-cell
dose (50×106).127
In the future, combination treatments using CAR T
cells directed against BCMA as well as additional antigens
may be needed to further improve clinical outcomes.
A SLAMF7-
targeting CAR, derived from elotuzumab,
has been developed, and T cells transduced with the
construct display anti-myeloma activity in vitro and in
mouse models.128 GPRC5D has been shown to be a potentially important target for the immunotherapy of MM, and
GPRC5D-targeted CAR T cells demonstrate preclinical
myeloma-directed activity in vitro and in vivo, including
in a BCMA antigen-escape model.129 Additionally, even
though abnormal plasma cells in MM generally do not
express CD19,130 a very small proportion of cancer stem
cells may retain the marker,131 opening the door to treatment with existing anti-CD19 CAR T therapies, such as
tisagenleceucel. In a study of 10 patients with RRMM who
received high-dose melphalan and autologous stem cell
transplant followed by infusion of CTL019 CAR T cells,
2 achieved longer PFS after HSCT+CTL019 compared
with prior HSCT (479 vs 181 days and 249 vs 127 days).
Durable response in this study was associated with the
induction of T cells against SOX2, a stem-cell antigen.132
A study of 21 patients with RRMM who received infusions
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of CD19-
targeting and BCMA-
targeting CAR T cells
reported 20 ORs (95%), including 9 sCRs (43%), 3 CRs
(14%), 5 VGPRs (24%) and 3 PRs (14%).133 Another trial
observed high initial response rates after administering
a combination of CAR T-BCMA and CTL119 (an investigational product with a humanized CD19-
targeting
CAR) as consolidation therapy to 10 patients responding
to third-line therapy, 4 of whom had high-risk cytogenetics. Absence of circulating B cells was observed in five
patients, including two who had ongoing responses at
4 months and 1 year, hinting at the desirable long-term
persistence of CAR T cells.134
Patient selection
The most frequent setting for clinical trials (and the
setting where the reported clinical results are the most
mature) are in the multiply relapsed/refractory space,
especially for trials in the USA. For inclusion in the
phase II KarMMa-1 trial of the BCMA-directed CAR T-cell
therapy bb2121, for example, patients must have received
three prior regimens including an IMiD, PI and an anti-
CD38 antibody, and have been refractory to the last
regimen. Because of the clinical setting, many patients
treated with CAR T cells have had MM with extensive
prior therapy.12 14 115 117 135–137 To date, there is no data
demonstrating differences in safety or efficacy based on
cytogenetics. As safety and efficacy is becoming apparent,
more advanced products are beginning to be explored
clinically in earlier lines, such as one to three prior therapies, and in the upfront setting for high-risk patient
populations.
Heavy pretreatment, including prior allogeneic transplant or other BCMA-targeting therapies, does not necessarily preclude patients from CAR T treatment. Safety
and possible efficacy was reported in a study by investigators from the Fred Hutchinson Cancer Research Center
using a vector identical to JCARH125 with unique manufacturing. In this study, seven patients with a median of
eight prior therapies, including autologous HSCT in 71%
and allo-HSCT in 43% of subjects were treated, none of
whom developed graft-
versus-
host disease (GVHD).137
In the phase I trial of bb2121, the median number of
previous regimens was seven in the dose-
escalation
cohort and eight in the expansion cohort, and manufacturing was successful for 100% of patients.12 Regardless
of prior therapies, an adequate number of lymphocytes
can usually be collected, and CAR T cells have been
successfully manufactured to the prespecified dose for
most patients on most trials.12 14 115 117 135–138 However, the
impact of previous chemotherapy on the quality of CAR
T cells is not yet known. While more study is required to
understand the benefit of repeat dosing at relapse with
the same CAR T-cell product, there have been reports in
the acute lymphoblastic leukemia (ALL) setting of clinical efficacy of retreatment in the presence of preserved
antigen expression with an intensified lymphodepletion
regimen.139 For MM, responses have also been reported
in relapsed patients treated with anti-BCMA CAR T cells,
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even after prior treatment with different BCMA-targeting
products, including CAR T cells.137
Performance status may be an important consideration
in recommending patients for trial enrollment. A study
evaluating JCAR017, an anti-CD19 CAR T, in relapsed/
refractory non-
Hodgkin’s lymphoma observed worse
outcomes in patients with impaired performance status,
defined as grade 2 on the Eastern Cooperative Oncology
Group (ECOG) scale. The overall mDOR was 5.0 months,
whereas the subset of patients scored ECOG 0–1 had an
mDOR of 9.2 months. Similarly, the 6-month OS was 75%
for all patients, and 88% for the ECOG 0–1 group.140
Recommendations
The decision of suitability for CAR T cell therapy is
often based on the potential for toxicity. Thus, baseline bone marrow function, cardiopulmonary, hepatic
and renal function as well as performance status and
organ status with respect to ability to tolerate CRS
should be evaluated and toxicities should be considered, especially prolonged cytopenias.
►► Registration trial results and FDA labels should guide
disease-
specific characteristics such as number of
prior antimyeloma therapies.
►► For patients earlier in their disease course, the presence of high-risk disease is an unmet medical need,
and may shift the benefit/risk calculation in support
of enrollment on cellular therapy trials.
►► Heavily pretreated patients, including those who have
undergone allo-HSCT may be considered for CAR T
cell therapy.
►► No data have been reported indicating that prior
bispecific antibody or ADC therapy impacts the potential efficacy of future CAR T cell therapy or vice versa,
and the panel agreed that there is not enough data
to report on a consensus. Future trials should seek to
address this question.
►► Myeloma disease progression kinetics and likelihood
of control should be weighed against the manufacturing time when considering patient eligibility for
collection and likelihood to be clinically stable for
CAR T cell administration.
►►

Administration, dosing and monitoring
CAR T cell therapy involves extensive collaboration across
the healthcare team. At the present time patients should
be referred to centers of experience for CAR T cell therapies. This may change as the community gains more experience with this therapeutic modality.141 Prior to infusion,
lymphodepletion is integral to CAR T cell treatment, and
an association between effective preconditioning and
consistent BCMA-targeting CAR T cell expansion has been
observed.142 The optimal conditioning regimen has yet to
be established, however experience from CD19-targeting
CAR T cell therapies indicates that a combination of
fludarabine and cyclophosphamide yields added benefits over single-
agent lymphodepletion.13 After dosing
of CAR T cells, patients must be monitored closely for
Shah N, et al. J Immunother Cancer 2020;8:e000734. doi:10.1136/jitc-2020-000734

toxicities, especially CRS and neurological events. Of the
approved CD19 CAR T cell products, axicabtagene ciloleucel requires daily monitoring at the treatment center
for 7 days after infusion,143 whereas tisagenlecleucel may
be given as outpatient, with patients being monitored
2–3 times during the first week following dosing.144 Both
instruct patients to stay within a 2 hours drive of the treatment facility for 4 weeks after infusion.
The characteristics of anti-BCMA CAR T therapy that
are amenable for outpatient management include a low
overall incidence of severe toxicities. For bb2121, most
cases of CRS were Lee Criteria grade 1 or 2 and the
frequency of grade 3 or 4 neurotoxicity was only 3%.12
Additionally, when severe toxicities do present, the
presentation typically has a slow, predictable progression over the course of days, such that worsening signs
and symptoms can be addressed in a timely fashion.145 146
However, treatment centers providing CAR T cell therapy
as an outpatient regimen will need to have the proper
infrastructure to support appropriate outpatient monitoring and rapid escalation to inpatient care, if needed.
The interpretation of bone marrow MRD status in MM is
not as straightforward as with other treatment modalities.
The patchy pattern of bone marrow infiltration typically
observed in MM generally leads to a degree of uncertainty
in the case of negative results.147 148 This is because MM
bone marrow burden of disease is cleared rapidly in many
cases, and clearance of the M-protein, which has a long
half-life, often lags behind. This is not an issue for patients
with light chain only disease, but for those with an M-protein a deepening of response by IMWG criteria is often
seen over time, thereby confounding interpretation of
persistent M-protein seen in patients with MRD-negative
responses in the marrow. Combined bone marrow MRD
assessment by MFC or NGS and 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography (PET)/CT may
yield more valuable information for predicting response
duration. A retrospective analysis of 103 patients with
newly diagnosed MM found significant differences in
4-year OS and PFS for patients who achieved negativity
by both PET and MFC (median PFS for PET−/MFC−
92 vs 28 months for PET+ patients; 4-year OS 94.2% for
PET−/MFC− patients vs 73.8% for PET+ patients).149 In
addition, the presence of more than three avid lesions by
PET/CT has been linked to inferior OS and shortened
PFS in several studies.150 However, this setting may not be
applicable to patients with RR disease receiving CAR T
cell therapy.
In the context of CAR T-cell therapy, in the bb2121
trial, achievement of MRD negativity was independent of
depth of response at the first assessment. Of the 9 out of
10 patients who achieved MRD, 2 were in CR by IMWG
criteria at the time of assessment and the remaining
seven achieved deeper responses over time. However,
1 MRD-negative patient became MRD-positive after 12
months and 1 MRD-
negative patient progressed as of
the data cut-off.151 MRD negativity did appear to associate with improved outcomes, however, out of 9 patients
13
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who achieved MRD negativity, 3 had at least 12-month
follow-up without progression by IMWG criteria. Importantly, the panel felt that PET-CT can be considered as
part of MRD evaluations, and FDG-avid disease should be
considered for biopsy before concluding that it is residual
or relapsing MM after CAR T cell therapy.
Panel recommendations
Patients should be re-
evaluated including disease
restaging prior to lymphodepletion if they received
cytotoxic bridging therapy or >30 days have passed
since apheresis.
►► Registration trial results and FDA labels should guide
lymphodepletion regimens.
►► The dose of fludarabine used for lymphodepletion in
patients with renal insufficiency should be reduced
per FDA prescribing guidelines.
►► Evidence of adequate blood counts based on complete
blood count should be present prior to lymphodepletion, unless impaired by disease burden.
►► If bridging therapy induces a CR, while data are limited,
the panel feels that the benefits of proceeding with
planned CAR T cell therapy in the heavily pretreated
RRMM setting regardless of CR outweighs the risk of
lower disease burden limiting CAR T cell expansion.
►► Patients may consider receiving CAR T cell therapy as
outpatient provided all the following criteria are met:
–– Patient has appropriate caretaker who can provide
24/7 support when the patient is away from the
outpatient facility.
–– Patient is compliant with medical management
instructions.
–– Patient meets clinical criteria for outpatient monitoring including stable vital signs, maintaining oral
intake and no impending clinical deterioration
from myeloma.
–– Patient has no active infection, increased risk for
CRS or neurotoxicity and no other clinical conditions requiring inpatient care.
–– Treatment center has appropriate infrastructure
to expedite care to inpatient if clinically indicated
24/7.
►►

Toxicities
The most commonly reported adverse event across all
CAR T clinical trials is CRS, with rates ranging from 37%
to 93% in patients with lymphoma treated with anti-CD19
CAR T cells and 77% to 93% in leukemia.152–157 CRS has
also been observed in patients with RRMM treated with
BCMA-directed CAR T cells.12 136–138 A consensus grading
system for CRS has been developed by the American
Society for Transplant and Cell Therapy (ASTCT),158 and
most clinical trials going forward in the MM setting are
using the ASTCT criteria. In the phase I trial evaluating
bb2121, 25 out of 33 patients experienced CRS, which
was grade 3 in 2 patients.12 Of the eight patients who have
been treated in 2018 with bb21217, a CAR T product
similar to bb2121 except that a PI3 kinase inhibitor is
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included during manufacturing to induce more of a
central memory phenotype, five developed CRS, with one
grade 3 case.136
Clinically, CAR T-associated CRS can range from mild
flu-like symptoms to multiple organ failure. Recognition
of CRS is vital in order to begin treatment, and high fevers,
hypoxia and hypotension are frequently observed early
symptoms. Severe CRS may be fatal and requires intensive
management, but most cases do resolve if care is initiated
quickly, including IL-6 blockade and steroids.153 156 157 159
The established protocol for IL-6 blockade involves tocilizumab, an antibody against the IL-6 receptor, initially
developed for rheumatoid arthritis, which was approved
in 2018 by the FDA for the treatment of CAR T cell-
induced CRS.160 161 Although some concerns have been
raised that steroids or IL-6/IL-
6R axis blockade may
impair T-cell proliferation, several reports have described
successful management of severe CAR T cell-associated
CRS using IL-6R-directed therapy and short-course corticosteroids without apparent compromise in expansion or
therapeutic efficacy.156 162 163 Theoretically, the anti-IL-6
antibody siltuximab could also be used to modulate the
damaging inflammatory pathology in CRS, although the
evidence for its efficacy is limited to two case reports.164 165
Blockade of IL-1 has been demonstrated to alleviate CRS
in mouse models,166 however the use of IL-1-modulatory
therapies in human patients treated with CAR T cells
remains anecdotal.
Transient neurological events, including confusion or
delirium, expressive aphasia, motor weakness, tremor,
headache, seizures and depressed level of consciousness
have been observed in nearly every trial targeting T cells
to CD19.167 The ASTCT criteria consider neurological
events separately from CRS, with an independent grading
system for immune effector cell-associated neurotoxicity
syndrome (ICANS).158 The pathophysiology of neurotoxicity remains poorly understood, but experience with
CD19-targeting CAR T cells for leukemia and lymphoma
suggest that elevated cytokine levels in the serum and
central nervous system (CNS) as well as blood-
brain
barrier disruption play a role.145 146 168 Notably, in studies
of CD19-
targeting CAR T cells, tocilizumab treatment
has not been associated with decreased incidence or
severity of ICANS.146 154 169–172 Some centers have moved
toward supportive care for CAR T cell-associated neurotoxicity, since most cases of low-grade ICANS resolve on
their own, while others favor aggressive early intervention with steroids.146 165 173 In the majority of trials with
BCMA-targeted CAR T cell therapy to date, severe CRS
and neurotoxicity have been less commonly seen than in
the registration trials for CD19-expressing malignancies.
Prolonged and recurrent cytopenias have also
frequently been observed in the CAR T cell trials reported
to date as a consequence of lymphodepleting chemotherapy, possibly compounded by a direct effect from
the CAR T cells themselves. Patients often need RBC and
platelet transfusion support within the first 3 months of
therapy.174–176
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Panel recommendations
The ASTCT consensus guideline grading system for
CRS and ICANS should be used to assess CAR T cell
toxicities in patients with myeloma.
►► To treat patients with CRS who do not respond to
tocilizumab and steroids, the panel could not reach
a consensus as to whether anakinra or siltuximab is
preferred.
►► For grade 1 CRS, tocilizumab may be considered,
especially in cases of patients with prolonged high
fevers, elderly patients or patients with significant
comorbidities.
►► Grade 2 or higher CRS should be managed with
prompt tocilizumab administration.
►► All patients should undergo comprehensive baseline
neurological assessment prior to CAR T cell dosing to
enable assessment for neurotoxicity signs and symptoms after infusion.
►► Initial management of neurotoxicity should be
based on experience and guidelines from registration trials, with escalation from supportive management to steroids, based on severity of signs and
symptoms.
►► Levetiracetam should be administered if seizures or
other evidence of severe neurotoxicity develop in the
context of CAR T cell therapy. Although no consensus
could be reached to recommend antiseizure medicines prophylactically, the panel was unanimous in
the opinion that there are few downsides to treating
with levetiracetam.
►► Patients may have had a high number of prior therapies before receiving CAR T cells, therefore, for
patients who have persistent cytopenia beyond 3
months, evaluation for other causes are recommended including infections such as CMV and parvovirus B19, and bone marrow examination to rule out
myelodysplastic syndrome (MDS).
►► If patients develop neutropenia during CAR T cell
therapy, filgrastim can be considered.
►► Patients should be monitored for blood count and
IgG levels regularly post-
CAR T cell infusion until
recovery.
►► IVIG supplementation should be considered for
patients with severe hypogammaglobulinemia (IgG
<400 mg/dL).
►► Macrophage
activation
syndrome/hemophagocytic lymphohistiocytosis (MAS/HLH)-
like toxicity
is potentially fatal, and for patients who do not
respond to tocilizumab and steroids, anakinra can be
considered.

►►

►►

Other considerations
CAR T cell safety when CrCl is <20 mL/min has not
been assessed and the majority of the panel would
not feel comfortable recommending CAR T therapy
for patients with renal failure or significant hepatic
impairment.

►►
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►►
►►

Viral prophylaxis should be administered during CAR
T cell therapy, and maintained through the treatment
period and the neutropenic period.
Pneumocystis jirovecii pneumonia prophylaxis should
be administered during CAR T cell therapy, although
a consensus could not be reached on the optimal
length of administration.
A consensus could not be reached to recommend
antifungal prophylaxis during CAR T cell therapy,
however, as more data accumulate this may require
further study.
A consensus could not be reached to recommend
antibacterial prophylaxis during CAR T cell therapy.
During influenza season, all patients should receive
the influenza vaccine prior to leukapheresis (if not
already administered in the current season) and if
lymphodepletion is not scheduled to start within 14
days. Influenza vaccines should be given with each
influenza season thereafter.

Bispecific T-cell engagers
Bispecific dual-targeting antibody constructs are designed
to help re-direct the immune system to carry out an attack
on tumor cells without extracting cells from the patient.
These agents often consist of mAbs with one binding site
activating
directed against the cytotoxic T lymphocyte-
receptor CD3-∈ and another against a tumor-
specific
antigen.177 These ‘off-
the-
shelf’ therapies may present
a more standard paradigm than treatment with CAR T
cells, circumventing the current laborious and expensive
procedures of extracting, engineering, and reinfusing
cells for treatment. However, they require repeat dosing,
and come with their own unique toxicities. Bispecific antibody and CAR T-cell therapies should not be considered
as interchangeable, and their relative clinical efficacies
are unknown.
Literature review
In 2019, only two bispecific antibody products were
approved: catumaxomab in Europe, for the treatment
of malignant ascites,178 and blinatumomab for relapsed
and refractory B-ALL.179 180 At the time of publication,
several bispecific cell engagers for the treatment of
MM are in development, listed in table 1. These could
eventually become options if results from early data are
confirmed in larger studies. A CD38-
targeting bispecific cell engager, GBR 1342, is undergoing a phase I
clinical trial (NCT03309111).181 Another anti-
CD38
bispecific cell engager, AMG 424, has demonstrated
tumor-growth inhibition in mice and peripheral B-cell
depletion in primates,182 and a phase I trial is underway
(NCT03445663). A phase I trial (NCT03399799) is
ongoing for JNJ-6440754, a bispecific T-
cell engager
targeting GPRC5D that has demonstrated tumor growth
suppression in preclinical models.183 A FcRH5-directed
bispecific cell engager, BFCR4350A, is also being evaluated in a phase I, multicenter, open-label, dose-escalation
study (NCT03275103).
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Table 1 Bispecific antibodies in development for the treatment of multiple myeloma
Name

Target antigen

Company

Trial ID

AMG-420
AMG-701

BCMA
BCMA

Amgen
Amgen

NCT02514239
NCT03287908

CC-93269

BCMA

Celgene

NCT03486067

PF-06863135

BCMA

Pfizer

NCT03269136

REGN-5458

BCMA

Regeneron

NCT03761108

TNB-383B

BCMA

Teneobio

NCT03933735

JNJ-64007957

BCMA

Johnson & Johnson/Genmab

NCT03145181

JNJ-64007564

GPRC5d

Johnson & Johnson/Genmab

NCT03399799

GBR-1342

CD38

Glenmark

NCT03309111

AMG-424
BFCR4350A

CD38
FCRH5

Amgen
Genetech

NCT03445663
NCT03275103

The most clinically mature bispecific cell engagers
target BCMA, with several agents in active phase I studies,
including JNJ-64007957 (NCT03145181), PF-06863135
(NCT03269136), AMG 420 (previously known as
BI836909), AMG 701 (NCT03287908), REGN5458
(NCT03761108) and REGN5459 (NCT04083534). In
2018, the FDA granted Fast Track Designation to AMG
420184 after encouraging results were reported from
a phase I first-in-human study. In the trial, there was a
70% (7/10) response rate at a dose of 400 µg/day (the
recommended dose for further investigation), with 5 of
7 responders achieving sCR. As of February 2019, some
responses had lasted longer than 1 year.20 However, as
AMG 420 is a dual-scFv ‘BiTE’ with short serum half-
life, the requirement for continuous infusions halted its
further development. An extended half-
life derivative,
AMG 701,185 is currently being evaluated in a phase I clinical trial (NCT03287908). Interim analysis of a phase I
trial of CC-93269, an asymmetric 2-arm humanized T-cell
engager that binds bivalently to BCMA and monovalently
to CD3, also reported promising efficacy and a manageable safety profile.186
The first-
in-
human phase I dose-
escalation study
(NCT02514239) for the anti-BCMA bispecific cell engager
AMG 420, demonstrated clinical activity in heavily
pretreated patients with RRMM.20 The study included at
least five 6-week cycles of AMG 420 administered until
PD, toxicity or consent withdrawal, followed by a potential five additional cycles for extended benefit. Patients
were eligible if they had progressive disease after ≥2 lines
of previous therapies, including PIs and IMiDs. Patients
were treated for a mean of 2.5 cycles. A dosage of 400 µg/
day (800 µg/day was determined intolerable, as two out
of three patients receiving this dose had dose-limiting
toxicities: one case of grade 3 CRS and one case of grade
3 peripheral neuropathy, both of which required hospitalization and subsequently resolved), this study reported
an ORR of 7/10 (70%), with five MRD-negative sCRs, one
VGPR and one PR. At the data cut-off date of December
2018, responses had lasted for 5.6–10.4 months with four
16

patients remaining on treatment. As of February 2019,
some responses lasted over 1 year. In total, 13/42 patients
demonstrated a response, with 6 sCRs, 3 CRs, 2 VGPRs
and 2 PRs. Treatment-related serious AEs included two
grade 3 peripheral neuropathies distinct from classic
CNS toxicity and one edema. Grade 2–3 CRS was seen in
three patients. Atypical infections including aspergillosis
and fulminant hepatitis related to adenovirus infection
were also observed.20 Another bispecific cell engager,
CC-93269, was evaluated in a phase I dose-finding trial
(NCT03486067), where eligible patients had RRMM and
had received ≥3 previous lines of treatment without prior
BCMA-
directed therapy. Of the 12 patients receiving
doses ≥6 mg/kg, the ORR was 83.3% and the median
time to response was 4.2 weeks (range 4.0–13.1). All 10
responses were ongoing with follow-up ranging from 2.1
to 4.7 months. Grade 3–4 treatment-emergent AEs were
reported in 15 (78.9%) patients and included 10 (52.6%)
patients with neutropenia, 8 (42.1%) with anemia, 5
(26.3%) with infections and 4 (21.1%) with thrombocytopenia. One patient who received 6 mg CC-93269 as
first dose and 10 mg on cycle 1 day 8 died on study in the
setting of CRS, with a potential infection as a contributing
factor. No patients required dose modifications.186
Patient selection
The efficacy and toxicity of bispecific cell engager therapy
targeting BCMA has not been fully elucidated to guide
a careful assessment of the risk/benefit ratio for participating populations. In general, the toxicities associated
with bispecific cell engagers have largely mirrored those
seen with other mAbs and T cell therapies including
CRS.177 However, notable unique toxicities, including
atypical infections and peripheral neuropathies, have
also been seen in trials. The population that has been
studied to date had relapsed/refractory disease after more
than two prior lines of therapy. Patients with plasma cell
leukemia, extramedullary relapse, CNS involvement or
prior allo-HSCT were excluded from the first-in-human
study of AMG 420.20 In the phase I trial of CC-93269, all 19
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patients who were treated had myeloma refractory to their
last line of therapy, with 16 (88.9%) refractory to dara,
17 (89.5%) to the most recently administered PI and 16
(84.2%) to the last IMiD. As more information becomes
available, however, treatment at an earlier line of therapy
or in the setting of high-risk disease will likely be evaluated.
Although still a subject of exploration, bispecific cell
engager therapy may also provide an effective option
for patients in cytogenetically high risk subsets, as
the features that render the disease more resistant to
standard biologic therapy may not apply to cell-based
immune therapies.187 188 Therefore, earlier therapy in
high-risk disease may provide a unique opportunity to
achieve more durable remission. Conversely, high-
risk
cytogenetics may be associated with higher levels of clonal
diversity and proliferation that may also allow for escape
mechanisms for T cell-mediated killing such as loss of
antigen expression (as has been observed with BCMA-
targeting CAR T cells189), higher levels of immunomodulatory cells in the microenvironment,190 upregulation
of negative costimulatory molecules and loss of HLA-
mediated presentation (as has been reported in patients
with acute leukemia after stem cell transplantation191 as
well as in mouse models of MM192). As such, the efficacy
of bispecific cell engager therapy will need to be assessed
in different disease subgroups.
Panel recommendations
To date, there is no consensus on the optimal indications for bispecific cell engager therapy. These agents
have been studied in patients who have relapsed/
progressed after standard treatments and were refractory to the last line of therapy, including PIs, IMiDs
and CD38 antibodies.

►►

Administration, dosing and monitoring
With limited clinical experience, there is no established
targeting bispecific cell
dosing schedule for BCMA-
engagers. Some bispecifics have short serum half-lives,
on the order of hours,193 necessitating continuous infusions. AMG 420 was given as continuous infusion over 4
weeks,20 which is also the recommended dosing schedule
for blinatumomab.194 However, an extended half-
life
BCMA-
targeting bispecific, AMG 701, has been developed, which shows robust antimyeloma activity in vitro.185
AMG 701 is currently being evaluated in a phase I clinical
trial (NCT03287908). During the first-in-human trial of
AMG 420, the maximum tolerated dose was 400 μg/day.
For CC-93269, continuous infusions were not necessary
and administration was intravenous over 2 hours on days
1, 8, 15 and 22 for cycles 1–3; days 1 and 15 for cycles 4–6;
and on day 1 for cycle 7 and beyond, all in 28-day cycles.
For dose escalation, CC-93269 was initially given in fixed
doses and in the second stage, patients received a fixed
first dose on cycle 1 day 1, followed by escalation on day
8. Doses ranged from 0.15 to 10 mg and the median duration of treatment was 14.6 weeks (range 1.6–32.0) with
patients receiving a median of 4 cycles (range 1–8).186
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During the AMG 420 trial, two deaths occurred,
neither of which were determined to be treatment
related: one patient succumbed to acute respiratory
distress arising from influenza and aspergillosis, the
other experienced fulminant hepatitis related to adenovirus infection. Of the 21 serious AEs reported during
the trial, 18 required hospitalization. The most common
serious AEs were infections (12 patients) and polyneuropathy (2 patients). Grade 2–3 CRS was also seen in
three patients.20 For CC-93269, CRS was reported in 17
(89.5%) patients and the majority of cases were grade
1 (n=11 (57.9%)) or grade 2 (n=5 (26.3%)), occurring
most frequently with the first or second dose (n=22 of
27 (81.5%)). Of the 27 total CRS events, 8 (29.6%) were
managed with dexamethasone and 10 (37.0%) with
tocilizumab. CRS prophylaxis with dexamethasone was
subsequently implemented with the first dose. Other
grade 3–4 AEs were reported in 15 (78.9%) patients,
including 10 (52.6%) with neutropenia, 8 (42.1%) with
anemia, 5 (26.3%) with infections and 4 (21.1%) with
thrombocytopenia.186
Experience with the approved bispecific, blinatumomab, as well as CAR T cell therapies may provide insight
on potential toxicities, with the caveat that the more
restricted expression profile of BCMA as compared with
CD19112 may alter toxicity profiles. Most cases of CRS
in the trials leading to the approval of blinatumomab
occurred during the first cycle, and during the phase III
randomized TOWER study comparing blinatumomab
with standard of care in relapsed and refractory acute
lymphoblastic leukemia (RR ALL), the median time to
first onset of any CRS event was 2 days and the median
time to onset for grade ≥ 3 CRS events was 4 days.195
Although no established biomarkers exist to predict CRS,
patients with higher disease burden may be at increased
risk.196 Patients with CRS are at increased risk for infections, and the signs and symptoms of CRS can mimic
those of sepsis, possibly delaying accurate diagnosis and
treatment.157 One patient in the CC-93269 trial died on
study in the setting of CRS, with potential infection as a
contributing factor.186
Monitoring response to bispecific cell engager therapy
is complicated by emerging data that MRD-
negative
responses can be independent of the depth of response
for T cell redirecting therapies by classical IMWG criteria
in the multiply RRMM population (see CAR T section for
discussion). During the bb2121 trial, the MRD-negative
patients who were not in CR by IMWG did achieve deeper
responses over time.151 Potential biomarkers of response
to bispecific cell engager therapy could include immunohistochemistry studies showing T cell localization into the
tumor bed, which possibly may be further augmented by
flow cytometric analysis of infiltrating T cell populations
with respect to expression of activation and inhibitory
markers as well as polarization as measured by cytokine
expression profiling, but the prognostic value of such
studies requires further investigation.
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Panel recommendations
The ASTCT consensus grading system for CRS and
ICANS should be used to evaluate toxicities associated
with bispecific cell engager therapy.
►► Toxicities should be managed as per established or
mandated investigational protocols.
►► As these therapies may eventually be administered
in the outpatient setting, it is important to recognize
that time to onset of CRS is typically within the first
2 days of beginning treatment, but may be delayed.
►► Atypical infections reported in one phase I trial of
AMG 420 suggest that attention should be paid to
monitoring for infectious sequelae.
►► A consensus could not be reached regarding how
to interpret MRD status as opposed to traditional
IMWG response criteria in both CAR T cell therapy
and bispecific antibody patients. However, there was
general consensus that MRD status can be a useful
tool for predicting favorable outcomes.
►►

Other considerations
Patients with autoimmune disease were excluded from
clinical trials for AMG 420, and the package insert for
blinatumomab lists autoimmune disease, acute GVHD
of grade ≥2 and active chronic GVHD as key exclusion
criteria.20 194 Patients with renal failure are typically
excluded from clinical trials, yet isatuximab, the CD38-
directed antibody, can be dosed in renal failure. Additionally, blinatumomab has been used in patients with CrCL
down to 30 mL/min. At present, little is known about the
mechanisms by which resistance arises to bispecific cell
engager therapies.

Antibody-drug conjugates
mAbs have become valuable components of combination regimens for the treatment of MM. Building on this
success, a new class of agents called ADCs has begun to
emerge for the treatment of hematological malignancies.
Consisting of three components: a mAb directed against
a tumor-specific antigen, a cytotoxic payload and a linker
that connects the targeting moiety to the cancer-killing
molecule,16 ADCs have demonstrated improved complete
remission rates and PFS in the treatment of B-ALL and
Hodgkin’s lymphoma in phase III and phase II trials.197 198
In the MM setting, a few ADCs, directed against different
cell-surface markers and carrying a variety of payloads,
are being evaluated in clinical trials.16
Belantamab mafodotin (GSK2857916) is an investigational ADC involving a humanized anti-BCMA mAb
conjugated to the cytotoxic agent monomethyl auristatin
F (MMAF) via a non-cleavable linker.199 In 2017, belantamab mafodotin was awarded Breakthrough Therapy
designation from the FDA and PRIME designation from
the EMA. Belantamab mafodotin is currently in clinical
development in patients with RRMM and other advanced
hematological malignancies expressing BCMA but is not
yet approved for use.
18

Literature review
The first-in-human, open-label, two-part, phase I study
DREAMM-1 (BMA117159; NCT02064387) investigated
belantamab mafodotin in adult patients with RRMM
after ASCT (or considered transplant ineligible), alkylators, PIs and IMiDs. In part 1 of the trial, 38 patients
were treated with escalating doses from 0.03 to 4.6 mg/
kg, with no dose-limiting toxicities identified. In part 2,
patients received belantamab mafodotin 3.4 mg/kg once
every 3 weeks for up to 16 cycles. Encouraging clinical
responses were observed, with an ORR of 60% (85% CI
42.1 to 76.1), PFS of 12.0 months (95% CI 3.1 to not
estimable (NE)), a mDOR of 14.3 months (95% CI 10.6
to NE) and median time to first response of 1.2 months
(95% CI 0.7 to 1.4). A confirmed OR was observed in
18/32 (56.3%; 95% CI 37.7 to 73.6) patients refractory to
both IMiDs and PIs, 15/21 (71.4%; 95% CI 47.8 to 88.7)
patients without prior dara treatment and 5/13 (38.5%;
95% CI 13.9 to 68.4) patients refractory to both IMiD and
PI with prior dara treatment.200 201 Overall, belantamab
mafodotin was well tolerated with rapid, deep and durable
responses in heavily pretreated patients with RRMM.
Additional follow-up confirmed CRs and considerably
longer PFS in the final analysis compared with interim
analysis. Patient experience of clinical benefit and tolerability was also evaluated through optional daily patient-
reported outcome (PRO) diaries and end-of-treatment
interviews. Twelve out of thirteen (92%) of interviewed
patients experienced a PR or greater by IMWG criteria.
During the end-of-treatment interview, patients reported
an average improvement in bone pain from 6.4 to 4.0
(scale 0–10). Fatigue ratings improved from 8.0 to 5.5.
Only four (31%) patients stated a decreased independence while on treatment. Overall treatment satisfaction
reached a mean of 8.1 (median=9.0) on a 0–10 point
scale.17 202
In the open-label, two-arm, phase II DREAMM-2 study
(NCT03525678), 196 patients with RRMM with disease
progression after three or more lines of therapy and
refractory to IMiDs and PIs and refractory or intolerant
(or both) to an anti-CD38 mAb were recruited, stratified
by previous lines of therapy (≤4 vs >4) and cytogenetic
risk status (42% and 47% with high-risk cytogenetics in
the 2.5 mg/kg treatment group and 3.4 mg/kg treatment
group, respectively) and randomized to receive 2.5 or
3.4 mg/kg belantamab mafodotin IV every 3 weeks on
day 1 of each cycle. As of June 21, 2019 (the primary
analysis data cut-off date), the ORR in the 2.5 mg/kg
cohort was 31% (30 patients, 97.5% CI 20.8 to 42.6) and
34% (34 patients, 97.5% CI 23.9 to 46.0) in the 3.4 mg/
kg cohort. Median PFS was 2.9 months in the 2.5 mg/
kg group and 4.9 months in the 3.4 mg/kg group, and
median OS was not reached.203 Various trials are also
underway using belantamab mafadotin in multiple
combinations, including with PIs (NCT03544281),
IMiDs (NCT03715478), and checkpoint inhibitors
(NCT03848845).
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Patient selection
ADC therapy has been the subject of trials in patients
with RRMM with progressive disease following IMID, PI,
anti-CD38 mAbs and stem cell transplant, if eligible.200
Subgroup analysis of part 2 of the DREAMM-1 trial
found an ORR of 71% for patients without prior dara
treatment and 38.5% in those patients with prior dara
exposure. Median PFS in the dara-refractory group was
6.8 months and in the subset of patients with prior dara
treatment and refractory to IMiDs and PIs, median PFS
was 6.2 months—encouraging, given the generally low
response rate seen in anti-CD38 refractory patients.201 In
the published results from the DREAMM-2 trial, although
no hypothesis testing was done in the prespecified analysis of ORR in individual subcohorts, 100% of patients in
the 2.5 mg/kg cohort and 97% of patients in the 3.4 mg/
kg cohort were refractory to dara.203
Panel recommendations
To date, there is no consensus on the optimal indications for ADC therapy. The agents have been
studied in patients who have relapsed/progressed
after standard treatments and were refractory to the
last line of therapy, including PIs, IMiDs and CD38
antibodies.
►► Patients with severe cytopenias (especially thrombocytopenia) or pre-existing corneal disease may be unsuitable for ADC therapy with belantamab mafodotin.
►► Although patients with prior allo-HSCT were excluded
from the DREAMM-1 and DREAMM-2 trials, based on
the known mechanisms of action for ADCs, patients
with prior allo-HSCT can be considered for treatment.
►►

Administration, dosing and monitoring
In the phase II registration study for belantamab
mafodotin, treatment continued until disease progression
or unacceptable toxicity occurred. The 2.5 mg/kg dose
was selected as the recommended dose for future monotherapy studies. During the trial, disease assessment was
completed every cycle using the IMWG uniform response
criteria.200 Premedication for IRRs was allowed on the
second dose onward in DREAMM-1 but was not mandated
in DREAMM-2. In the DREAMM-2 study, premedications
for IRRs was not mandated per the protocol. Additionally,
monitoring for corneal events is recommended with ADC
therapy, based on the frequency of ocular AEs reported
across clinical trials.204 All patients in the DREAMM-1 trial
received steroid eye drops to mitigate corneal events.
Toxicities
All patients receiving the phase II dose in the DREAMM-1
trial experienced at least one adverse event. Grade 3 or
4 AEs were reported in 28 (80%) of 35 patients, most
commonly thrombocytopenia (12 patients) and anemia
(5 patients). The most common serious AEs were IRRs
and lung infections. Ocular AEs were also common,
with 16 patients (46%) reporting blurred vision and 12
(34%) experiencing dry eyes (although only 1 case of dry
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eyes was grade 3).200 Ocular toxicities are a commonly
reported adverse event with ADC treatment, although
the precise mechanism remains unknown. AEs have been
seen most frequently in ADCs using the combination of
SPDB (a cleavable disulfide linker) and the mayatanisoid
DM4 or maleimidocaproyl (a non-cleavable linker) and
the auristatin MMAF.204 Belantamab mafodotin carries
MMAF as its toxic payload, and corneal events were
common in the DREAMM-1 trial. Most patients did have
corneal findings on examination, most commonly superficial punctate keratitis, although the majority were classified as mild in severity.200 In the DREAMM-2 trial, the
most common grade 1–2 adverse event was keratopathy
and the most common grade 3–4 AEs in the population
were keratopathy in 26 (27%) and 21 (21%) of patients in
the 2.5 and 3.4 mg/kg cohorts, respectively, thrombocytopenia (19 (20%) and 33 (33%)) and anemia (19 (20%)
and 25 (25%)). Two potentially treatment-related deaths
occurred: one case of sepsis in the 2.5 mg/kg cohort and
one case of HLH in the 3.4 mg/kg cohort. Four patients
(one in the 2.5 mg/kg cohort and three in the 3.4 mg/
kg cohort) permanently discontinued treatment because
of keratopathy. Among patients with keratopathy worse
than baseline at the end of treatment, the events resolved
in 9 (36%) of 25 patients in the 2.5 mg/kg cohort, with
a median time to resolution of 71 days (interquartile
range (IQR) 57–99), and 8 (28%) of 29 patients in the
3.4 mg/kg cohort, with a median time to resolution of
96 days (70–127). No benefit was observed for prophylactic steroid eyedrop administration, as median time to
keratopathy was similar between eyes treated prophylactically with corticosteroid eye drops and without (24 (IQR
21–30) and 27 (21–42) days, respectively in the 2.5 mg/kg
cohort and 25 (9–40) and 25 (21–40) days, respectively in
the 3.4 mg/kg cohort).203
Panel recommendations
Prior to receiving belantamab mafodotin the
patient should receive a complete ophthalmological
examination.
►► Monitoring in the initial studies included weekly
complete blood counts and complete metabolic
panels. After the first few cycles or after blood counts
normalize, testing can be reduced to occur every
treatment cycle.
►► Management of corneal toxicity includes use of
preservative-free lubricant eye drops as needed for
symptoms of dryness, blurry vision or photophobia.
►► Management of moderate-
to-severe corneal toxicity
includes holding therapy until improvement of symptoms to grade 1 or less and improvement of corneal
changes is confirmed by ophthalmological examination, then restarting with a one level dose reduction.
►► During belantamab mafodotin treatment specifically,
therapy can be restarted once keratopathy or other
AEs (such as cytopenias) have resolved to grade 1 or
less. Dose reduction from 3.4 to 2.5 mg/kg may be
►►
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►►

considered. Further dose reductions to 1.9 mg/kg
may be done if significant toxicity recurs.
Since a proportion of patients may have delayed
responses, it is recommended that ADC therapy be
continued as long as patients exhibit stable disease or
better responses and are tolerating therapy.

Other considerations
No validated biomarkers exist to predict response to
ADC therapy. In the phase I DREAMM-1 trial, no clear
association was observed between predose soluble BCMA
concentrations and response to treatment.200 Patients
with significant renal insufficiency, plasma cell leukemia
and hepatic impairment were excluded from clinical
trials of belantamam mafodotin. A trial of the ADC brentuximab vedotin in patients with CD30+ hematological
malignancies and hepatic or renal impairment observed
increased exposure to the cytotoxic payload molecule,
MMAE, among patients with deficient liver or kidney
function.205 Anecdotally, patients with chronic hepatitis B
infection on entecavir have been successfully treated with
ADCs and exhibited good tolerability and response.
Although belantamab mafodotin is the most clinically
advanced, ADCs targeting other antigens and carrying
other payloads have been investigated. Indatuximab
ravtansine (BT-062) is an ADC carrying the microtubule-
disrupting maytansinoid DM4 as payload and targeted to
CD138, which is overexpressed on MM cells. In a phase
I trial of 35 patients with RRMM, indatuximab ravtansine monotherapy resulted in a 5.9% ORR with no CR,
although 61.8% of patients achieved stable disease. The
median OS and PFS were 26.7 and 3 months, respectively.18
A phase I/II trial evaluating indatuximab ravtansine in
combination with low-dose dexamethasone and lenalidomide in 47 patients with RRMM observed a median PFS
of 16.4 months. Of the 43 who patients completed at least
two treatment cycles and were evaluable for response, 33
achieved PR or better, with an ORR of 77% and a mDOR
of 21.0 months.206 Despite these results, in 2017, ImmunoGen announced that it has elected not to exercise its
late-stage co-development option with Biotest to develop
BT-062 for the US market.207
Lorvotuzumab mertansine (IMGN901) is an anti-CD56
targeting mAB linked to the maytansinoid DM1. The
agent demonstrated no clinical benefits in a phase II study
evaluating combination therapy with carboplatin and
etoposide in 141 patients with small-cell lung cancer.208
In RRMM, however, IMGN901 has delivered modest clinical benefits. In a phase I/II study, the objective response
rate was only 5.7%, but stable disease or better was noted
in 42.9% of patients treated with single agent lorvotuzumab mertansine, and the mDOR was 15.5 months.209
Another ADC, milatuzumab doxorubicin (hLL1-DOX),
which delivers a DNA-
damaging anthracycline molecule to cells expressing CD74, also maintained stable
disease for longer than 3 months in 5 out of 19 patients
with RRMM in a multicenter dose-
escalation study.210
However, a subsequent trial of hLL1-DOX, completed in
20

2015 (NCT01101594) posted no results, and no further
studies have been registered with the agent.

Vaccines
Cancer vaccines targeting MM represent an attractive
strategy to reverse critical aspects of the immunosuppressive milieu of the tumor microenvironment and promote
the activation and expansion of tumor-specific lymphocytes. Potential antigenic targets include the use of shared
tumor antigens such as cancer testis antigens (NY-ESO),
plasma cell-specific markers (BCMA), oncogenic drivers
(MUC1) and the clonal idiotype. A growing area of
interest is the use of neoantigens derived from unique
mutational events. Several of the current vaccine strategies were reviewed in the prior SITC consensus statement
on immunotherapy for the treatment of hematological
malignancies.24
One antigen-specific approach that is being explored
in the setting of SMM is the PVX-410 vaccine, which
consists of a cocktail of HLA-A2-derived peptides from
X-box binding protein 1, CD138 and SLAM-F7 antigens
that can trigger activation of MM-specific T cells.22 Alternatively, investigators have examined strategies to load
antigens derived from whole tumor cells onto antigen-
presenting cells. In one approach, a personalized vaccine
has been created in which hybridomas are created from
patient-
derived myeloma cells fused with autologous
dendritic cells (DCs). In a phase I study, vaccination
with the DC/MM fusions in conjunction with granulocyte macrophage colony-
stimulating factor resulted
in a durable expansion of myeloma-
reactive CD4+
and CD8+ lymphocytes, and ongoing stable disease in
three patients, with no evidence of progression at 12, 25
and 41 months.23 Based on these results, this approach is
now being tested in a randomized multicenter phase II
clinical trial being conducted through the Clinical Trials
Network cooperative group (CTN 1401, NCT02728102).
Study enrollment of >200 patients has been completed
with site-specific production of vaccine and centralized
vaccine characterization and determination of immunological response.
The use of vaccine therapy will likely be most efficacious as a strategy to enhance native T cell immunity
to target lower volume disease such as after autologous
transplantation and as a potential combinatorial strategy
to enhance effector cell therapies. As one example, the
potential synergy between the DC/MM fusion vaccine and
BCMA CAR T cells is being explored to assess whether
vaccination may result in epitope spreading and greater
persistence of the CAR T cell population.
Panel recommendations
►► The panel did not make any recommendations
regarding the use of vaccines in myeloma. Participation in well-designed clinical trials is encouraged.
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Quality of life and patient engagement
Immunotherapy is changing the outlook for patients with
MM. Data are limited on how immunotherapy affects QoL,
but answering this question is increasingly important as
our effective therapies evolve and the number of survivors
grows. There is thus a need to identify late physiological
effects and psychosocial needs, and develop evidence-
based interventions.
Patient and caregiver education
Education for immunotherapies must emphasize the
unique mechanisms of action and side-
effect profiles,
as they differ from chemotherapy and targeted therapies. Side effects vary among the various immunotherapy
agents. Since immunotherapy is a complex modality
with numerous agents and diverse side effects administered in different settings, all healthcare professionals
must also be scrupulously educated. It is also important
that patients with myeloma receive care from a specialist
in hematological malignancies—a 2018 survey of 2382
patients with myeloproliferative neoplasms revealed that
only one-third were treated by a specialist.211
For the current immunotherapies discussed in these
SITC guidelines, the common immune related side
effects include IRRs to antibodies (see ‘Daratumumab’,
‘Elotuzumab’, ‘Isatuximab’ and ‘Antibody-
drug conjugates’ sections), as well as CRS and ICANS for CAR T cell
and BiTE therapies (see ‘CAR T cells’ and ‘Bispecific T
cell engagers’ sections). The majority of IRRs occur with
the first or second exposure to antibodies, but they may
also occur with any subsequent infusions. Some events,
such as CRS and ICANS, may be delayed.
Panel recommendations
Education must prepare the patient and caregivers
for the timeline of expected side effects. It is critical
to educate patients and caretakers about the signs
and symptoms of immune-related side effects because
early recognition is essential to effective treatment.
►► Caregiver education is paramount as neurological
toxic effects may impair a patient’s ability to recognize
symptoms.
►► It is crucially important to also coordinate education
with the interdisciplinary care team. This may include
provider, advanced practice provider, nurse, coordinator (research or non-research), social worker and
pharmacist.
►►

Quality of life considerations for administration, dosing and
monitoring during immunotherapy
mAbs are associated with typical IRRs (see ‘Daratumumab’, ‘Elotuzumab’ and ‘Isatuximab’ sections). A
clinical review of mAbs in myeloma212 emphasizes the
need for appropriate preinfusion and postinfusion medications to lower the rates of IRRs and facilitate increases
in infusion rates to enable shorter infusion time.
For cellular therapies, many institutions prefer continuous toxicity monitoring and have limited ambulatory
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programs, so the majority of CAR T cell patients receive
their initial care in the inpatient setting.213 However,
outpatient management is permitted on the label of at
least one FDA-approved CAR T therapy for lymphoma.
Research will need to identify methods to improve early
detection and intervention for toxicities, such as an
electronic medical record alert, medical alert bracelet,
emergency department protocols for fast-tracking evaluation and admission and 24-hours access to specialized
physicians for diagnosis and early management. Psychosocial criteria for CAR T cell therapy (such as proximity
to treating institutions and need for a 24-hour caretaker)
could potentially improve the promptness of medical
attention, however, this needs to be studied.
In the long term, there is an effort to protect patients
who are receiving genetically modified cellular therapy
products. The FDA requires patients receiving tisagenlecleucel and axicabtagene ciloleucel to participate in
15 years of postmarketing participation in observational
study for long-term safety and risk of secondary malignancies.143 144
Panel recommendations
Patient monitoring and management depends on the
immunotherapy agent.
►► All patients receiving immunotherapies should be
given detailed call parameters specific to their treatment so patients can promptly communicate with
their cancer care providers for direction.
►►

Special considerations for quality of life
Clinical trials often have more frequent assessments and
clinic visits than standard of care therapies. This places an
additional burden on the patient—physically, emotionally
and financially. Additionally, patients receiving treatment
on an immunotherapy clinical trial may be required to
remain in proximity to the treating institution and have
a 24-hour caretaker for a period of time, which would
further increase the burden.
Financial toxicity is an important side effect of cancer
treatment and a psychological stressor.214 Although at
the time of this writing, there is not an FDA-approved
CAR T cell therapy for myeloma, it can be surmised that
a myeloma CAR T cell therapy would be similarly priced
to the currently available commercial CAR T cell products. Cost of treatment alone, not including hospital
care or services provided, for a course of tisagenlecleucel
(Kymriah) or axicabtagene ciloleucel (Yescarta) for
lymphoma is US$373,000, and the price of tisagenlecleucel for B-ALL is US$475,000. Ancillary expenses such
as transportation, relocation costs and accommodations,
food and child care215 also contribute to financial distress.
Kymriah and Yescarta Risk Evaluation and Mitigation Strategies (REMS) programs both instruct patients to remain
within proximity of the treating institution for at least 4
weeks following infusion,143 144 and one could postulate a
similar requirement for a myeloma therapy. This requirement obviously adds to the ancillary costs of treatment.
21
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Panel recommendations
Patients should be referred for a social work evaluation to assess needs and connect to available resources.
►► It is especially important to provide whole-
person
care. Patients should be connected to other patients,
survivors, support groups and online forums, and
referrals should be made to social workers, chaplains
and psycho-oncologists.
►► Recommended advocacy groups include the International Myeloma Foundation (www.myeloma.org),
Multiple Myeloma Research Foundation (
www.
themmrf.org), Leukemia & Lymphoma Society (www.
lls.org), Myeloma Crowd (www.myelomacrowd.org)
and the SITC (sitc.org).
►► Ideally,
immunotherapy-
specific
survivorship
programs should be developed or patients receiving
immunotherapy should be included in existing
programs.
►►

Immunotherapy-specific quality of life
There are very limited data describing the impact of
immunotherapy on QoL. In a secondary analysis of MAIA,
which compared health-related quality of life (HRQoL)
between treatment arms (D-Rd vs Rd), the D-RD arm
demonstrated an improvement in HRQoL.216 As assessed
by the European Organization for Research and Treatment (EORTC) Quality-
of-
life Questionnaire Core
30 (QLQ-
C30), improvement in Global Health Status
occurred in both groups. However, the D-Rd arm demonstrated significantly greater improvement earlier (cycle
3) and increasing improvement over time. The D-Rd arm
also showed significant improvement and clinically meaningful benefit in HRQoL as evaluated by the EQ-5D-5L
Visual Analog Scale. This was evidenced by a longer time
to worsening in the D-Rd arm and meaningful differences
in pain symptoms and cognitive functioning, although
the decline in cognitive functioning was not significant
between arms.
Analysis of patient-
reported health status in the
ELOQUENT-3 trial as quantified by the MD Anderson
Symptom Inventory MM module and the three-
level
version of the EuroQoL 5 Dimensions Questionnaire (EQ-5D-3L) in patients treated with elotuzumab
compared with those receiving Pd alone showed no worsening of pain, fatigue or bone aches with elotuzumab
treatment and minimal differences in QoL between
patients who received EPd and Pd.217
Data are lacking on the impact of CAR T cell therapies
on short-term and long-term QoL. However, clinical trials
are beginning to include QoL assessment in addition to
efficacy. Preliminary data on QoL in CAR T cell patients,
in comparison with HSCT patients, were presented at
The 24th Congress of the European Hematology Association.218 These data demonstrate that CAR T cell therapy
at least does not significantly worsen QoL compared
with autologous and allo-
HSCT. Furthermore, in the
short term there is some indication of improved physical
well-being.
22

How and how often QoL should be assessed in patients
receiving immunotherapy has not been established,
although recommendations are starting to emerge.
Level VI evidence (semi-structured interviews and focus
groups encompassing 20 patients) from Osborne et al
demonstrated that existing QoL measures developed
and validated for MM do not capture all the QoL issues
important for patients with myeloma. A new myeloma-
specific QoL questionnaire designed specifically for use
in the clinical setting—the MyPOS—was developed based
on the findings of Osborne et al.219 However, currently the
EORTC QLQ-C30 is the most validated tool for HRQoL in
myeloma. In 2018, the Medicare Evidence Development
& Coverage Advisory Committee (MEDCAC) extended
coverage for CAR T cell therapy for beneficiaries with
advanced cancer, and the panel mostly endorsed the incorporation of Patient Reported Outcomes (PRO) tools for
CAR T cell therapies. The MEDCAC voting members had
highest confidence in the Patient-
Reported Outcomes
Measurement Information System (PROMIS).220 There
are not yet validated PRO tools for CAR T cell therapy,
but a recent review221 advocates for the use of PROMIS as
it has been universally validated for HSCT.
Panel recommendations
►► Validated tools, including EORTC QLQ-
C30 and
PROMIS, should be considered in evaluation of
effects of immune therapies on QoL.
Immune-related side effects and quality of life
Although some interview and focus group data222 suggest
that some patients’ treatment decisions are impacted by
treatment attributes, the panel’s experience is that treatment efficacy is more important to patients than side
effects. Significant associations have been seen between
longer treatment-
free intervals and better HRQoL for
patients with MM,223 opening up the possibility that CAR
Tcell therapies and ADCs with finite treatment schedules
could improve QoL.
As noted in previous sections, common side effects of
immunotherapies that may persist after the initial treatment period include cytopenias, heightened risk for
viral, bacterial and fungal infections, immunodeficiencies and fatigue. Treatment guidelines to manage these
events are generally institution-specific (growth factors,
prophylactic antimicrobial, transfusions, IVIG). However,
it is important for providers to assess for these side effects
with some frequency and to also work with local providers
in following these toxicities closely.
Panel recommendations
Patients should be educated on the potential need
for prophylactic antimicrobials, IVIG and/or growth
factor and transfusion support to manage cytopenias
and immunodeficiency.
►► Patients should also be educated that they may experience fatigue as a sequelae of cellular and immunotherapy. Pharmacological and non-
pharmacological
►►
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interventions may be used to address fatigue, although
it is important to avoid steroids as treatment because
of the concern of T cell suppression.
Conclusions
With demonstrated clinical benefit including deep and
durable responses in both the newly diagnosed and
relapsed/refractory setting, immunotherapies are rapidly
becoming mainstays in the treatment of MM. As more
novel agents make their way through clinical trials, it will
be important to characterize if and how prior treatment
with one immunotherapeutic agent influences the efficacy of subsequent lines of therapy. Furthermore, with
more approved options, trials evaluating combination
regimens could examine potential synergies between
immunotherapeutic agents. For example, bispecific T
cell engager antibodies might enhance cytotoxic T cell
activity when given after cancer vaccination or CAR T cell
therapy. As with any regimen, however, rigorous randomized controlled trials will need to be performed to demonstrate safety and efficacy. Future studies will also need to
address the interpretation of response criteria and MRD
in the context of patients treated with immunotherapies.
Finally, patient access to immunotherapy and QoL during
and after treatment should not be ignored by practicing
physicians. It is an exciting time for the MM field, as new
agents are prolonging survival and improving outcomes
in a disease that was once universally and rapidly fatal.
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MULTIPLE MYELOMA CIG CLINICAL SURVEY RESULTS
These survey items served as the foundation for consensus recommendations within the SITC Multiple
Myeloma Cancer Immunotherapy Guideline. Further discussion during the expert panel meeting, draft
revisions, and teleconferences were used to refine and develop guideline recommendations derived
from but not identical to statements captured in these results.
1. What best describes your primary role?
a. Medical oncologist—18%
b. Hematologist—12%
c. Hematologist/Oncologist—65%
d. Surgical Oncologist
e. Radiation Oncologist
f. Nurse practitioner
g. Nurse (RN)
h. Patient Advocate
i. Other: Hematopathologist—6%
2. Which treatment(s) do you administer yourself on a regular basis for Multiple Myeloma patients?
(Check ALL that apply)
a. Chemotherapy
b. Radiation Therapy
c. Targeted Therapy
d. Immunotherapy—30%
e. Clinical Trials—6%
f. All of the Above—58%
g. Other: I do not treat patients—6%
3. Which of the following factors influences your recommendations for treatment with
immunotherapy? (Check ALL that apply)
a. Patient age—100%
b. Performance status—100%
c. Presence of recurrent and/or metastatic disease—100%
d. Prior therapy exposure (chemotherapy)—88%
e. Prior therapy exposure (radiation)—6%
f. Prior therapy exposure (surgical)—0%
g. Prior therapy exposure (bone marrow transplant)—41%
h. Prior therapy exposure (other immunotherapies)—47%
i. Relevant biomarker status—6%
j. Clinical trial availability—12%
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Daratumumab
1. In which patients would you feel comfortable using daratumumab? (Please select ONE
response)
a. Severe renal insufficiency (CrCL<30)—35%
b. Liver failure
c. Both—53%
d. All Patients—6%
e. Neither—6%
2. How would you incorporate daratumumab into the treatment of patients with plasma cell
leukemia? (Please select ONE response)
a. I would not use datatumumab until more data is available in this patient population—
18%
b. I would use daratumumab, extrapolating from combinations tested and felt to be safe in
patients with MM—53%
c. I would use daratumumab in combinations outside of those tested in patients with
MM—23%
d. Not Applicable–6%
3. Do you routinely use IVIG supplementation in patients receiving daratumumab-based
therapy? (Please select ONE response)
a. Yes, I use it in all my patients—82%
b. No, I do not use it in any patients—12%
c. I administer IVIG using similar criteria for every regimen, and my criteria are not specific
to daratumumab
d. Not Applicable—6%
4. In your relapsed patients requiring treatment where you will likely use both a daratumumabcontaining regimen and an elotuzumab-contatining regimen, what is your order of
preference? (Please select ONE response)
a. I would use an elotuzumab regimen followed by a daratumumab regimen—24%
b. I would use a daratumumab regimen followed by an elotuzumab regimen—59%
c. The order does not matter—17%
5. What frontline dara-containing regimen(s) would you feel comfortable recommening for
transplant-eligible patients (select all that apply)?
a. D-VMP—7%
b. D-Rd—40%
c. D-VRd—87%
d. D-KRd—67%
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6. Do you reconsider going back to weekly dosing if patients progress on monthly dosing of
dara?
a. Yes—64%
b. No—36%

Elotuzumab
1. Would you ever feel comfortable recommending elotuzumab-containing regimens in the
front-line setting?
a. Yes—20%
b. No
2. Do you recommend elotuzumab-contaning regimens for patients with rapidly growing
disease burdens?
a. Yes—13%
b. No—87%
3. For previously treated multiple myeloma, would you feel comfortable recommending
elotuzumab plus bortezomib and dexamethasone?
a. Yes—53%
b. No—47%
4. Would you feel comfortable recommending elotuzumab-containing regimens for patients
who have progressed on daratumumab-containing regimens?
a. Yes—87%
b. No—13%
5. Would you feel comfortable using elotuzumab in patients with severe renal insufficiency
(CrCL<30)?
a. Yes—87%
b. No—13%
6. Would you feel comfortable using elotuzumab in patients with hepatic impairment ?
a. Yes—67%
b. No—33%
7. Would you feel comfortable using elotuzumab in patients with plasma cell leukemia ?
a. Yes—33%
b. No—67%

Isatuximab
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1. In patients with pulmonary disease (decreased FEV1 in pulmonary function tests) do you use any
additional premedication? (Please select ALL that apply)
a. Albuterol inhaler—6%
b. Albuterol nebulizer—6%
c. Albuterol inhaler or nebulizer—12%
d. None
e. Montelukast—76%
f. Other: ____________________
2. As first-line therapy in patients with relapsed myeloma, would you recommend a combination
therapy based on daratumumab, elotuzumab or isatuximab? (Please select ONE response)
a. Elotuzumab
b. Daratumumab—35%
c. Isatuximab
d. Depending on patient and relapse—59%
e. Not applicable—6%
3. For newly diagnosed multiple myeloma patients, which treatment would you recommend?
(Please select ONE response)
a. Isatuximab + VRd—77%
b. VRd alone—23%
4. Which of the following factors influences your decision NOT to give Isatuximab to a patient with
newly diagnosed multiple myeloma? (Choose all that apply)
a. Patients who have progressed on a daratumumab containing regimen—12%
b. Patients that have had an allergic reaction to isatuximab or its components—18%
c. Prior adjuvant therapy within 6 months
d. Prior treatment exposure (Other mAbs, chemotherapy)
e. Patient age (e.g functionally > 80)—6%
f. Performance status
g. Tumor mutational load
h. History of potentially life threatening AI condition and/or need for immunosuppressive—6%
therapy
i. Recent History of cardiovascular co-morbidities
j. No experience with this drug—35%
5. Which of the following factors influences your decision NOT to give Isatuximab to a patient with
refractory multiple myeloma (1 or more prior lines of therapy)? (Choose all that apply)
a. Patients who have progressed on a daratumumab containing regimen—24%
b. Patients that have had an allergic reaction to isatuximab or its components—29%
c. Prior adjuvant therapy within 6 months
d. Prior treatment exposure (Other mAbs, chemotherapy)—17%
e. Patient age (e.g functionally > 80)
f. Performance status
g. Tumor mutational load
h. History of potentially life threatening AI condition and/or need for immunosuppressive
therapy—12%
i. Recent History of cardiovascular co-morbidities
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No personal experience with this drug—17%

6. Does cytogenetic risk status impact your decision to prescribe isatuximab? (Please select ONE
response)
a. Yes - Patients with high risk cytogenetics may have a lower response rate compared to
patients with standard risk myeloma—12%
b. Yes – Patients with low risk cytogenetics may have a lower response rate compared to
patients with standard risk myeloma—6%
c. No—71%
d. Not Applicable—12%
7. If a patient has progressed on a regimen containing daratumumab in a prior line of therapy and
you are considering using a CD38 antibody again in a subsequent line of therapy, which agent
would you favor using again as the preferred CD38 antibody? (Please select ONE response)
a. Isatuximab—53%
b. Daratumumab—47%

8. In which patients would you feel comfortable using isatuxumab? (Please select ONE
response)
a. Severe renal insufficiency (CrCL<30)—29%
b. Liver failure
c. Both—36%
d. Neither—29%
9. Would you feel comfortable using isatuxumab in patients with COPD?
a. Yes—71%
b. No—29%

CAR T cell therapies
1. What is the preferred sequence for T cell redirection therapies? (Please select ONE response)
a. Bi-specific > CAR T17%
b. CAR T > Bi-specific—24%
c. Agnostic to sequence—59%
2. What is the preferred sequence for BCMA-directed therapies? (Choose all that apply)
a. ADC before T cell directed therapy—18%
b. T cell directed therapy before ADC—29%
c. After one T cell directed therapy (CAR or Bi-specific), try an ADC before trying the other T
cell directed therapy—18%
d. Agnostic to sequence—41%
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3. In clinical trials, bridging therapies are typically exclusively therapies which have been used
prior for that patient. How would you approach other strategies for bridging therapy? (Please
select ONE response)
a. Only use treatments which the patient has been exposed to prior—12%
b. Would be willing to use any treatments which the patient is naïve to—59%
c. Would be willing to use some treatments which the patient is naïve to—12%
d. Not Applicable—6%
4. How would you proceed if bridging therapy induces a complete response prior to CAR T
administration? (Please select ONE response)
a. Proceed with planned CAR T therapy regardless of complete response—59%
b. Do not proceed with CAR T if patient achieves MRD (negative) complete response—24%
c. Do not proceed with CAR T if patient achieves any complete response—12%
d. Not Applicable—6%
5. If lymphodepletion using fludarabine is not possible due to patient renal function, how would
you proceed? (Please select ONE response)
a. Do not proceed with CAR T therapy—24%
b. Proceed with CAR T therapy, omit lymphodepletion
c. Proceed with CAR T therapy, use cytoxin alone—76%
6. If a patient with CRS does not respond to treatment with tocilizumab and steroids, how would
you proceed? (Please select ONE response)
a. Siltuximab—29%
b. Anakinra—59%
c. Depends on results of lab tests such as cytokine levels—12%
7. When do you use anti-seizure medication in the context of CAR T therapy? (Please select ONE
response)
a. As prophylaxis at the time of CAR T administration—35%
b. At the onset of any neurotoxicity symptom—35%
c. Following diagnosis of seizure activity—12%
d. With grade 3 or higher neurotoxicity—6%
e. Persistent grade 2 or higher neurotoxicity—6%
f. Not Applicable—6%
8. Which of the following tests do you do to restage patients 1 month post-administration of
CAR T therapy? (Choose all that apply)
a. Serologic study—94%
b. Urine protein study—71%
c. Bone marrow assessment—94%
d. PET
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e. I do not restage following CAR T therapy—6%
9.

When do you typically assess MRD status? (Please select ONE response)
a. Prior to serological/urine CR status is achieved
b. At the same time that serological/urine CR status is being tested—41%
c. Following CR status by serological/urine test—47%
d. At landmark analyses—6%
e. Not Applicable—6%

10. Which of the following do you provide prophylactic therapy for following CAR T therapy?
(Choose all that apply)
a. Bacterial infection—70%
b. Viral infection—88%
c. Fungal infection—65%
11. When providing anti-infectious prophylaxis following CAR T therapy, how long do you provide
prophylaxis? (Choose all that apply)
a. A fixed duration—24%
b. Until blood count recovers—65%
12. When using G-CSF with CAR T therapy, under what circumstances to you use it? (Please select
ONE response).
a. At a fixed time period (specify time period) ____________
b. If patient is neutropenic—35%
c. If patient develops neutropenic fever
d. If patient develops neutropenia and has an active infection—12%
e. I do not regularly use G-CSF during CAR T therapy—18%
f. Other (please specify)______________
13. What are your criteria for treatment of CAR T patients with IVIG supplementation? (Please
select ONE response).
a. IgG below 400 mg/dL—47%
b. IgG below 400 mg/dL AND severe infection—12%
c. IgG below 400 mg/dL AND multiple infections—24%
d. Other—12%
e. Not Applicable—6%
14. Which of the following would cause you to exclude a patient from CAR T therapy (Choose all
that apply)
a. Renal failure and on hemodialysis—76%
b. Active plasma cell leukemia (no CNS assessment performed)—41%
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c. Active plasma cell leukemia (CNS assessment)—35%
d. Active CNS involvement—70%
e. History of CNS involvement—6%
15. Which of the following would you consider in conjunction with CAR T therapy? (Choose all
that apply)
a. Etoposide—12%
b. Cyclophosphamide—100%
c. Anti-thymocyte globulin (ATG)—6%
16. What do you consider to be required neurologic testing prior to CAR T therapy?
a. Yes always, with a brain MRI—35%
b. Yes always, with testing tools per treating physician—17%
c. Not necessary unless determined so by treating physician—41%
d. Not Applicable—6%
17. Do you routinely employ EEG as part of neurological testing prior to CAR T therapy?
a. Yes
b. No—100%
18. How should cerebral edema during CAR T therapy be managed?
a. Mannitol—6%
b. Continued EEG monitoring
c. Conitnued ICP monitoring—6%
d. A, B and C—35%
e. Per treating physician judgement—41%
f. High-dose steroids—6%
19. Should patients with have persistent detectable systemic M protein with negative bone
marrow and PET be managed differently versus patients in CR by IMWG criteria?
a. Yes—94%
b. No—6%
20. How often should PET or other imaging be performed after CAR T therapy?
a. Every 3 months for 1 year then every 6 months up to 2 year—23%
b. Every 6 months until year 3—12%
c. Per treating physician preference—12%
d. Once to confirm CR and then only as clinically indicated—47%
e. Not Applicable—6%
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21. Would you consider additional tests such as serum circulating BCMA for BCMA targeting CAR T
to follow disease status after CAR T therapy?
a. Yes—59%
b. No—41%
22. Are current assays to quantify BCMA expression sufficiently robust?
a. Yes—12%
b. No –88%
23. Is soluble BCMA a marker of disease relapse?
a. Yes—59%
b. No—41%
24. How should relapse following CAR T cell therapy be treated?
a. Similar to other episodes of relapse—35%
b. With continued immune-based therapy—29%
c. With another BCMA-directed therapy
d. Only at clinically significant relapse—18%
e. Other—18%
25. Should patients be evaluated for an anti-CAR T cell immune response following relapse?
a. Yes—82%
b. No—12%
26. Should patients ever be retreated with the same CAR T cell product following relapse?
a. Yes—23%
b. No, never—6%
c. Yes, but only if there was a CR and response of > 3 months—47%
d. Other—25%
27. Should CAR-T cell dose be titrated based on disease burden?
a. Yes—29%
b. No—71%
28. Should vaccination decisions post-CAR T cell therapy be based on serology titers? (obtained
after discontinuation of IVIG therapy >2 months)
a. Yes—59%
b. No—41%
29. At what time point should serology titers be obtained after vaccination?
a. 3 months after vaccination—29%
b. 6 months after vaccination—53%
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c. Other—18%
30. If lymphodepletion with fludarabine is not possible as part of the usual Fly/Cy regimen, would
you feel comfortable using cyclophosphamide alone?
a. Yes—73%
b. No—27%
31. How would you proceed if bridging therapy induces a complete response prior to CAR-T
administration? (Please select ONE response)
a. Proceed with planned CAR-T therapy regardless of complete response—87%
b. Do not proceed with CAR-T if patient achieves any complete response—13%
32. What is your preferred regimen for patients with grade 2 CRS?
a. Tocilizumab + steroids—73%
b. Tocilizumab alone—27%
c. IL-1 blockade
d. Other (please specify)
33. During CAR T therapy do you recommend viral prophylaxis?
a. Yes—93%
b. No—7%
34. For what duration do you maintain viral prophylaxis?
a. Through the treatment period
b. Through the treatment period and the neutropenic period—20%
c. Through the treatment period, the neutropenic period and an additional 6 to 12 months—
68%
d. I do not recommend viral prohylaxis—6%
e. Never stop—6%
35. During CAR T therapy do you recommend fungal prophylaxis?
a. Yes—67%
b. No—33%
36. For what duration do you maintain fungal prophylaxis?
a. Through the treatment period—6%
b. Through the treatment period and the neutropenic period—60%
c. Through the treatment period, the neutropenic period and an additional 6 to 12 months
d. I do not recommend fungal prophylaxis—28%
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e. Only if persistently neutropenic—6%
37. During CAR T therapy do you recommend Pneumocystis jirovecii pneumonia (PcP)
prophylaxis?
a. Yes—80%
b. No—20%

38. For what duration do you recommend Pneumocystis jirovecii pneumonia (PcP) prophylaxis?
a. Through the treatment period—6%
b. Through the treatment period and the neutropenic period
c. Through the treatment period, the neutropenic period and an additional 6 to 12 months—
36%
d. I do not recommend PCP prophylaxis—21%
e. Other—37%
39. During CAR T therapy do you recommend prophylaxis against other bacterial infections?
a. Yes—53%
b. No—47%
40. For what duration do you recommend prophylaxis against other bacterial infections?
a. Through the treatment period
b. Through the treatment period and the neutropenic period—60%
c. Through the treatment period, the neutropenic period and an additional 6 to 12 months
d. I do not recommend prophylaxis against other bacterial infections—40%
e. Other (specify)
f.

Antibody-drug conjugate
1. How should ADC therapy be used in patients who have previously received T-cell
redirection therapy? (Please select ONE response)
a. ADC directed to the same target as T cell redirection—12%
b. ADC directed to an alternate target—65%
c. Other—23%
2. Which of the following factors influences your decision NOT to administer ADCs to a
patient with multiple myeloma? (Choose all that apply)
a. Renal failure—47%
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Hepatic impairment—65%
Chronic hepatitis B infection (medicated)—6%
Chronic hepatitis B infection (unmedicated)—35%
Plasma cell leukemia diagnosis—29%
Would consider all patients—6%
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